Cells undergo metabolic adaptation during environmental changes by using evolutionarily conserved stress response programs. This metabolic homeostasis is exquisitely regulated, and its imbalance could underlie human pathological conditions. We report here that C9orf72, which is linked to the most common forms of the neurodegenerative diseases amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), is a key regulator of lipid metabolism under stress. Loss of C9orf72 leads to an overactivation of starvation-induced lipid metabolism that is mediated by dysregulated autophagic digestion of lipids and increased de novo fatty acid synthesis. C9orf72 acts by promoting the lysosomal degradation of coactivator-associated arginine methyltransferase 1 (CARM1), which in turn regulates autophagy-lysosomal functions and lipid metabolism. In ALS/FTD patient-derived neurons or tissues, a reduction in C9orf72 function is associated with dysregulation in the levels of CARM1, fatty acids, and NADPH oxidase NOX2. These results reveal a C9orf72-CARM1 axis in the control of stress-induced lipid metabolism and implicates epigenetic dysregulation in relevant human diseases.
Cells undergo metabolic adaptation during environmental changes by using evolutionarily conserved stress response programs. This metabolic homeostasis is exquisitely regulated, and its imbalance could underlie human pathological conditions. We report here that C9orf72, which is linked to the most common forms of the neurodegenerative diseases amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), is a key regulator of lipid metabolism under stress. Loss of C9orf72 leads to an overactivation of starvation-induced lipid metabolism that is mediated by dysregulated autophagic digestion of lipids and increased de novo fatty acid synthesis. C9orf72 acts by promoting the lysosomal degradation of coactivator-associated arginine methyltransferase 1 (CARM1), which in turn regulates autophagy-lysosomal functions and lipid metabolism. In ALS/FTDpatient-derived neurons or tissues, a reduction in C9orf72 function is associated with dysregulation in the levels of CARM1, fatty acids, and NADPH oxidase NOX2. These results reveal a C9orf72-CARM1 axis in the control of stress-induced lipid metabolism and implicates epigenetic dysregulation in relevant human diseases.
Nutrient utilization and energy metabolism are critical for the maintenance of cellular homeostasis, and their dysregulation could lie at the origin of many human diseases. Glucose and lipids are two main energy sources in energy homoeostasis. During compensatory responses to energy shortage such as glucose starvation, lipids serve as the source of energy supply, providing the fatty acids (FAs) whose metabolism is crucial for the survival of cells, including neurons (Du et al. 2009; Cabodevilla et al. 2013). FAs are stored as triacylglycerols that form lipid droplets (LDs), which are organelles consisting of a core of lipid esters covered by a phospholipid monolayer. LDs are dynamic organelles involved in lipid metabolism. The process of LD biogenesis is not entirely clear, but LD formation is known to occur in the endoplasmic reticulum (ER) (Fujimoto and Parton 2011). When mammalian cells experience starvation conditions, LD biogenesis is elevated (Rambold et al. 2015), and, at the same time, the turnover of LDs is increased, releasing free FAs (FFAs) (Fujimoto and Parton 2011). The turnover of LDs is reported to be mediated by macroautophagy (referred to here as autophagy) (Singh et al. 2009), a lysosome-degradative process used for degrading or recycling organelles in response to stress to maintain cellular homeostasis.Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by progressive degeneration of motor neurons. The hexanucleotide repeat expansion in C9orf72 is the most common cause of both ALS and the related neurodegenerative disease frontotemporal dementia (FTD) (DeJesus-Hernandez et al. 2011; Renton et al. 2011). In addition to the toxicity resulting from the expanded repeat (Taylor et al. 2016), the reduction in C9orf72 transcript and protein levels in patient cells and brain tissue suggests that loss-of-function mechanisms may contribute to ALS and FTD pathogenesis (DeJesus-Hernandez et al. 2011; Gijselinck et al. 2012; Belzil et al. 2013; Ciura et al. 2013; Donnelly et al. 2013; Mori et al. 2013; Xi et al. 2013; Haeusler et al. 2014; Liu et al. 2014; Waite et al. 2014). Additionally, there has been one report of a loss-of-function splice site mutation in C9orf72 causing ALS (Liu et al. 2016). Furthermore, higher C9orf72 levels may have beneficial effects against neurodegeneration in humans (van Blitterswijk et al. 2015; McGoldrick et al. 2018). Moreover, loss of C9orf72 hypersensitizes cells to stress (Maharjan et al. 2017), and the haploinsufficiency of C9orf72 leads to neurodegeneration in human motor neurons (Shi et al. 2018). Still a poorly characterized protein, C9orf72 has been shown to possess the structural components of a DENN (differentially expressed in normal and neoplasia)-like protein by bioinformatics analysis (Zhang et al. 2012; Levine et al. 2013). Recent studies have suggested that C9orf72 regulates membrane trafficking, the autophagy–lysosome pathway, and autoimmunity (Farg et al. 2014; Amick et al. 2016; Burberry et al. 2016; O'Rourke et al. 2016; Sellier et al. 2016; Sullivan et al. 2016; Ugolino et al. 2016; Webster et al. 2016; Yang et al. 2016; Aoki et al. 2017; Jung et al. 2017); however, the molecular functions of C9orf72 remain poorly understood. Energy metabolism defects have been associated in ALS patients, including hypermetabolism and hyperlipidemia (Dupuis et al. 2008, 2011; Dorst et al. 2011). This hypermetabolism results at least in part from an increased resting energy expenditure in ALS patients (Bouteloup et al. 2009; Vaisman et al. 2009), reflecting an altered basal metabolic rate. However, there has been no molecular mechanism identified to explain the ALS-related defects in energy and lipid metabolism.Here, we report that C9orf72 regulates the lipid metabolism in the cell, particularly under conditions of glucose starvation stress. Mechanistically, C9orf72 controls the turnover of its interactor, coactivator-associated arginine methyltransferase 1 (CARM1), which serves as an epigenetic activator of autophagy and FA synthesis genes. CARM1 is dysregulated in mice lacking C9orf72 and in human cells and tissues derived from patients with C9orf72-linked ALS/FTD. Our study reveals a previously unknown C9orf72–CARM1 axis that plays a key role in the regulation of lipid metabolism and may have implications for the pathogenesis of relevant neurodegenerative diseases.
Results
Loss of C9orf72 alters lipid metabolism under starvation
To identify the cellular processes affected by the loss of C9orf72, particularly under nutrient stress, we performed a quantitative whole-proteome analysis of C9orf72 knockout (C9KO) and wild-type mouse embryonic fibroblasts (MEFs) under glucose starvation as well as control (complete medium [CM]) conditions by using tandem mass tag (TMT)-labeling mass spectrometry (MS). The quantitative analysis showed that more lipid metabolism-related proteins were differentially regulated in C9KO MEFs than in wild-type cells under glucose starvation (Supplemental Fig. S1A,B), suggesting that the loss of C9orf72 alters lipid metabolism under the starvation stress. Furthermore, among the proteins that were differentially regulated by the loss of C9orf72 after glucose starvation, there was a significant enrichment in proteins related to lipid synthesis (Supplemental Fig. S1C,D). To examine the potential C9orf72-dependent defects in lipid metabolism, we first measured the total cellular lipid concentration in C9KO and wild-type MEFs under both well-fed and starvation conditions. The levels of lipids were similar between C9KO and wild-type MEF cells when they were cultured with CM or starved for only a short time (6 h) (Fig. 1A). Consistent with previous analysis showing that lipids are increased under starvation conditions because of enhanced lipid biogenesis (Kaushik and Cuervo 2015), prolonged glucose starvation for 16 h increased the lipid levels (Fig. 1A). Interestingly, under this condition, the lipid levels were significantly elevated in the absence of C9orf72. Given that LDs are the main cell organelles for lipid storage, we quantified the amounts of LDs by staining cells with a well-characterized lipid probe: boron-dipyrromethene (BODIPY493/503) (Singh et al. 2009). Again, no difference was observed in LD amounts between wild-type and C9KO cells when cultured with CM. However, LD signals were significantly increased in the C9KO MEFs after starvation in glucose-free medium for 16 h (Fig. 1B,C).
Figure 1.
Loss of C9orf72 alters lipid metabolism under glucose starvation. (A) Wild-type and C9KO MEFs were starved with glucose-free medium for the indicated hours, and the lipid amount at each time point was detected by a fluorometric lipid-binding assay as described in the Materials and Methods. n = 3. (B,C) Wild-type and C9KO MEFs were cultured with CM or starved with glucose-free medium for 16 h, and LDs were stained by BODIPY493/503. The number of LDs per cell was counted, and 50 cells per group from three independent experiments were analyzed. (D,E) Wild-type and C9KO MEFs cultured with CM or starved with glucose-free medium (16 h) were triple-labeled with LDs by BODIPY493/503 and ER marker calnexin for confocal immunofluorescence microscopy analysis. The colocalizations of BODIPY493/503 and calnexin per cell were analyzed by Pearson's R-value. Thirty cells in each group from three independent experiments were statistically analyzed. (F) Wild-type and C9KO MEFs were starved with glucose-free medium for 0, 6, and 16 h. The FFA amounts were determined by an enzyme-coupled fluorometric assay as described in the Materials and Methods. n = 3. (GS) Glucose starvation. Data are presented as mean ± SEM. (*) P < 0.05; (**) P < 0.01; (***) P < 0.001.
Loss of C9orf72 alters lipid metabolism under glucose starvation. (A) Wild-type and C9KO MEFs were starved with glucose-free medium for the indicated hours, and the lipid amount at each time point was detected by a fluorometric lipid-binding assay as described in the Materials and Methods. n = 3. (B,C) Wild-type and C9KO MEFs were cultured with CM or starved with glucose-free medium for 16 h, and LDs were stained by BODIPY493/503. The number of LDs per cell was counted, and 50 cells per group from three independent experiments were analyzed. (D,E) Wild-type and C9KO MEFs cultured with CM or starved with glucose-free medium (16 h) were triple-labeled with LDs by BODIPY493/503 and ER marker calnexin for confocal immunofluorescence microscopy analysis. The colocalizations of BODIPY493/503 and calnexin per cell were analyzed by Pearson's R-value. Thirty cells in each group from three independent experiments were statistically analyzed. (F) Wild-type and C9KO MEFs were starved with glucose-free medium for 0, 6, and 16 h. The FFA amounts were determined by an enzyme-coupled fluorometric assay as described in the Materials and Methods. n = 3. (GS) Glucose starvation. Data are presented as mean ± SEM. (*) P < 0.05; (**) P < 0.01; (***) P < 0.001.Since the ER is the main cellular organelle for LD biogenesis (Wilfling et al. 2014) and our proteomic analysis indicated an enrichment of ER proteins among differentially regulated proteins in C9KO cells under glucose starvation (Supplemental Fig. S1E), we examined the formation of LDs in the ER of C9KO MEFs. When the MEFs were cultured in CM, colocalization of LDs with the ER was only rarely observed in either wild-type or C9KO MEF cells, suggesting a low basal level of lipid biogenesis in the ER in both cell types (Fig. 1D,E). When the cells were starved in glucose-free medium for 16 h, the colocalization of the LDs and ER was increased in both the wild-type and C9KO MEF cells. However, the C9KO MEFs exhibited more LDs colocalized with the ER than the wild-type cells did under this condition (Fig. 1D,E). These data suggest that loss of C9orf72 increases LD biogenesis under glucose starvation condition.FAs, stored as triglycerides, are the major component of lipids in LDs. When released from triglycerides, FFAs are the main energy source for lipid utilization under conditions of starvation. We therefore tested the FFA levels in the C9KO and wild-type cells. In wild-type MEFs, the FFA level was initially slightly decreased after 6 h of treatment in the glucose-free medium but then increased sharply after 16 h of treatment (Fig. 1F). By comparison, the FFA levels in the C9KO MEFs were increased at both 6 and 16 h after glucose starvation (Fig. 1F). Furthermore, the C9KO cells exhibited higher levels of FFA than wild-type cells for the duration of the glucose starvation conditions (Fig. 1F).
Loss of C9orf72 increases FA flux and biogenesis
To determine whether the FFA accumulation under glucose starvation conditions in C9KO cells resulted from an increase in extracellular FFA uptake or intracellular biogenesis, we first examined the capacity for cellular uptake of extracellular FFA using a dodecanoic acid fluorescent FA substrate. We found no difference in the FFA uptake ability between the C9KO and wild-type MEF cells under well-fed or glucose-starved conditions (Supplemental Fig. S2A), suggesting that the FFA accumulation in the C9KO cells was due to intrinsic changes in the FFA biogenesis. Next, we examined the activities of two major intracellular FFA-generating pathways, including LD digestion and de novo FA synthesis.Autophagy promotes FA flux by digesting LDs and organelle membranes into FAs, which are used to generate increased amounts of LDs (Kaushik and Cuervo 2015). Given the recent suggestion that C9orf72 is involved in the regulation of autophagy (Ugolino et al. 2016; Yang et al. 2016), we asked whether the increase of FFAs in C9KO MEFs upon glucose starvation was a result of augmented autophagic activity. We first investigated the status of autophagic flux in wild-type and C9KO MEF cells under glucose starvation conditions by monitoring the turnover of LC3II, a common marker for autophagic activity. There was no difference in the LC3II levels between wild-type and C9KO MEFs after glucose starvation (Supplemental Fig. S2B). However, after treatment with bafilomycin A1, an autophagy inhibitor that prevents lysosomal degradation of LC3II, C9KO MEFs exhibited significantly more LC3II than did wild-type controls (Supplemental Fig. S2B), indicating an enhanced autophagic flux in the glucose-starved C9KO MEFs. In addition, when the cells were treated with both glucose starvation and bafilomycine A1, there were more LC3-positive puncta in the C9KO MEFs than in the wild-type controls (Supplemental Fig. S2C,D). Thus, the loss of C9orf72 led to an enhanced autophagic flux under glucose starvation conditions, which is consistent with the previous reports that C9orf72 is a negative regulator of autophagic flux (Ugolino et al. 2016; Yang et al. 2016).To confirm that the autophagy-mediated LD digestion was increased in the absence of C9orf72, we examined the colocalization of LDs with lysosomes as described previously (Singh et al. 2009; Seo et al. 2017). The colocalization of the BODIPY and LAMP1 signals was increased under glucose starvation conditions when compared with well-fed cells (Fig. 2A,B), consistent with the previous reports that the digestion of LDs by the autophagy is enhanced under starvation conditions (Kaushik and Cuervo 2015). Notably, under this condition, there was a significantly higher degree of colocalization of BODIPY and LAMP1 in C9KO MEFs than in wild-type cells. Next, we isolated LDs from these cells and measured the levels of LC3 and p62 proteins as markers for autophagic digestion of these lipid organelles. The adipose differentiation-related protein (ADRP) was used as a loading control (Singh et al. 2009). The LDs isolated from C9KO MEFs showed significantly higher levels of LC3II and p62 than did wild-type cells under glucose starvation conditions (Fig. 2C), indicative of an increased lipophagy. To confirm that the increase in the level of LDs in the absence of C9orf72 is dependent on the autophagy–lysosome pathway, we used bafilomycin A1 to inhibit lysosomal activity. The treatment of bafilomycin A1 reversed the increase in the level of LDs in the absence of C9orf72, as indicated by the BODIPY staining, and resulted in comparable levels of LDs in C9KO and wild-type MEFs (Supplemental Fig. S2E,F), demonstrating that the increase in LDs depends on lysosomal activity. To further confirm the involvement of the autophagy–lysosome pathway, we blocked autophagy induction by depleting Atg5 or FIP200 in C9KO MEFs. The complete removal of Atg5 from C9KO MEFs reversed the increase in the levels of LDs and lipophagy as quantified by the number of LDs per cell and their colocalization with LAMP1 (Fig. 2D–F). Furthermore, reducing FIP200 by shRNAs similarly ablated the increases in the levels of LDs and lipophagy in C9KO MEFs (Supplemental Fig. S2G–I). Together, these data indicate that loss of C9orf72 stimulates glucose starvation-induced LD digestion through the autophagy–lysosome pathway.
Figure 2.
Loss of C9orf72 increases FA flux and biogenesis. (A,B) Wild-type and C9KO MEFs were starved with glucose-free medium for 16 h, and then the association of autophagy with LDs was monitored by immunostaining of BODIPY and lysosomal marker LAMP1. The number of BODIPY and LAMP1 double-positive puncta per cell was counted, and 30–40 cells in each group from three independent experiments were statistically analyzed. (C) Wild-type and C9KO MEFs were grown with or without glucose starvation for 16 h, and then LDs were isolated and subjected to SDS-PAGE and immunoblot against anti-LC3 and P62. ADRP served as a loading control. The ratios of LC3II/I and the amounts of P62 were calculated and statistically analyzed. n = 3. (D–F) Wild-type, C9KO, and C9/Atg5 double-knockout MEFs were starved with glucose-free medium for 16 h. The LDs were labeled with BODIPY and counted, and the association of autophagy and LDs was monitored as in A. Twenty-eight to 30 cells in each group from three independent experiments were statistically analyzed. (G) Wild-type and C9KO MEFs were cultured in CM or glucose-free medium with [1,2-14C] acetate at a final concentration of 0.3 µCi for 6 h. The incorporation of [1,2-14C] in total lipids was measured by a scintillation counter. Counts per minute (CPM) were normalized to the total amount of protein. n = 6. (H–J) Wild-type and C9KO MEFs were grown in glucose-free medium, and the protein levels of acetyl-CoA carboxylase (ACC) and NOX2 were determined at the indicated time points by immunoblotting. n = 3. (GS) Glucose starvation. Data are presented as mean ± SEM. (*) P < 0.05; (**) P < 0.01.
Loss of C9orf72 increases FA flux and biogenesis. (A,B) Wild-type and C9KO MEFs were starved with glucose-free medium for 16 h, and then the association of autophagy with LDs was monitored by immunostaining of BODIPY and lysosomal marker LAMP1. The number of BODIPY and LAMP1 double-positive puncta per cell was counted, and 30–40 cells in each group from three independent experiments were statistically analyzed. (C) Wild-type and C9KO MEFs were grown with or without glucose starvation for 16 h, and then LDs were isolated and subjected to SDS-PAGE and immunoblot against anti-LC3 and P62. ADRP served as a loading control. The ratios of LC3II/I and the amounts of P62 were calculated and statistically analyzed. n = 3. (D–F) Wild-type, C9KO, and C9/Atg5 double-knockout MEFs were starved with glucose-free medium for 16 h. The LDs were labeled with BODIPY and counted, and the association of autophagy and LDs was monitored as in A. Twenty-eight to 30 cells in each group from three independent experiments were statistically analyzed. (G) Wild-type and C9KO MEFs were cultured in CM or glucose-free medium with [1,2-14C] acetate at a final concentration of 0.3 µCi for 6 h. The incorporation of [1,2-14C] in total lipids was measured by a scintillation counter. Counts per minute (CPM) were normalized to the total amount of protein. n = 6. (H–J) Wild-type and C9KO MEFs were grown in glucose-free medium, and the protein levels of acetyl-CoA carboxylase (ACC) and NOX2 were determined at the indicated time points by immunoblotting. n = 3. (GS) Glucose starvation. Data are presented as mean ± SEM. (*) P < 0.05; (**) P < 0.01.Next, we asked whether loss of C9orf72 enhances de novo FA synthesis, a pathway that could provide a new carbon source for the increased lipid metabolism. We used the radiolabeled [1,2-14C] acetate, a precursor of acetyl-CoA, to trace newly synthesized FAs in wild-type and C9KO MEFs under well-fed and glucose starvation conditions. We found that the incorporation of 14C into the lipids was significantly increased in C9KO MEFs compared with wild-type controls under the glucose starvation condition (Fig. 2G), indicating that loss of C9orf72 results in enhanced de novo synthesis of lipids under the nutrient stress. Next, we investigated whether FA de novo synthesis was altered upon the loss of C9orf72. Two enzymes regulating FA de novo synthesis were found to be up-regulated, including acetyl-CoA carboxylase (ACC) and FA synthase (FASN) (Fig. 2H,I; Supplemental Fig. S2J). Among them, ACC is the rate-limiting enzyme controlling the critical step of FA de novo synthesis (Currie et al. 2013). In both wild-type and C9KO MEFs, glucose starvation increased the level of ACC proteins. Under glucose starvation conditions, C9KO MEFs showed significantly higher ACC levels than wild-type MEFs (Fig. 2H,I). FASN showed changes similar to ACC in C9KO under glucose starvation conditions (Supplemental Fig. S2J). These data suggest that loss of C9orf72 heightens the activation of ACC and FASN, which is consistent with the increased lipid and FFA levels in the cells lacking C9orf72. Additionally, while studying the molecular consequences of the altered lipid metabolism in the absence of C9orf72, we found a consistent increase in the level of the NADPH oxidase NOX2. NOX2 is the most studied NADPH oxidase family member and was reported to be activated by FFAs (Inoguchi et al. 2000). NOX2 is also known to cause oxidative stress and has been found to be up-regulated in the nervous tissues of ALS patients (Wu et al. 2006; Marden et al. 2007). We confirmed that treatment with a common FA, sodium palmitate, resulted in a dose-dependent increase in the levels of NOX2 in MEFs by Western analysis (Supplemental Fig. S2K). Furthermore, we found that NOX2 was increased in C9KO MEFs upon glucose starvation compared with wild-type MEFs (Fig. 2H,J). These results suggest that loss of C9orf72 could contribute to the up-regulation of NOX2 and related pathogenesis in ALS patients.
C9orf72 negatively regulates CARM1 protein level
We then investigated the molecular mechanism underlying C9orf72-mediated regulation of lipid metabolism. In a quantitative proteomic study for C9orf72-interacting proteins using stable isotope labeling by amino acids in cell culture (SILAC) MS, we identified CARM1 as a potential strong interactor of C9orf72 (Supplemental Table S1). CARM1 is a transcriptional regulator that influences autophagy through an epigenetic mechanism (Shin et al. 2016). Hence, we asked whether CARM1 is the critical player that links C9orf72 to the regulation of autophagy and lipid metabolism.First, we tested CARM1 protein levels upon C9orf72 depletion. Under basal condition, loss of C9orf72 increased CARM1 protein levels in C9KO MEFs (Fig. 3A,B). Additionally, CARM1 was up-regulated by glucose starvation, as reported previously (Fig. 3A,B; Shin et al. 2016). Notably, a longer duration of glucose starvation—up to 16 h—led to a greater increase in the CARM1 levels in C9KO MEFs than in wild-type cells (Fig. 3A,B). To further confirm the specificity of the regulation of CARM1 by C9orf72, we generated stable knockdown HEK293 cell lines using shRNAs against C9orf72. Like the C9KO MEFs, the HEK293 cells with stable C9orf72 knockdown exhibited up-regulation of CARM1 protein when compared with control cells, and this up-regulation could be further amplified by glucose starvation (Supplemental Fig. S3A). Conversely, overexpressed C9orf72 in HEK293 cells reduced CARM1 protein levels markedly under both well-fed and starvation conditions (Fig. 3C). Finally, we performed a rescue experiment by stably expressing humanC9orf72 in the C9KO MEFs. With the restoration of the C9orf72 protein level, the accumulated CARM1 protein caused by loss of C9orf72 was brought down to the normal level of the wild-type cells (Fig. 3D).
Figure 3.
C9orf72 negatively regulates CARM1 protein level. (A,B) After glucose starvation for 0, 6, and 16 h, wild-type and C9KO MEFs were lysed, and CARM1 expression was determined by immunoblotting. n = 3. (C) Flag-tagged human C9orf72 was expressed in HEK293 cells, which were grown with or without glucose starvation for 6 h. The cells were then analyzed for CARM1 expression by immunoblotting. (D) The rescue of C9orf72 levels by stably expressing human C9orf72 in C9KO MEFs reversed the increase in CARM1 protein level under 6-h glucose starvation back to the wild-type level. (E,F) Cerebral cortex lysates from 2-mo-old wild-type and C9KO mice with or without 24-h fasting conditions were analyzed for CARM levels by immunoblotting. n = 3. (GS) Glucose starvation. Data are presented as mean ± SEM. (*) P < 0.05; (**) P < 0.01.
C9orf72 negatively regulates CARM1 protein level. (A,B) After glucose starvation for 0, 6, and 16 h, wild-type and C9KO MEFs were lysed, and CARM1 expression was determined by immunoblotting. n = 3. (C) Flag-tagged humanC9orf72 was expressed in HEK293 cells, which were grown with or without glucose starvation for 6 h. The cells were then analyzed for CARM1 expression by immunoblotting. (D) The rescue of C9orf72 levels by stably expressing humanC9orf72 in C9KO MEFs reversed the increase in CARM1 protein level under 6-h glucose starvation back to the wild-type level. (E,F) Cerebral cortex lysates from 2-mo-old wild-type and C9KO mice with or without 24-h fasting conditions were analyzed for CARM levels by immunoblotting. n = 3. (GS) Glucose starvation. Data are presented as mean ± SEM. (*) P < 0.05; (**) P < 0.01.To determine whether this regulation holds true under physiological conditions, we analyzed the CARM1 protein levels in brains from C9KO mice and gender-matched wild-type littermate controls with or without fasting treatment. C9KO mice showed significantly higher levels of CARM1 than wild-type controls (Fig. 3E,F). Furthermore, the difference between the protein levels of CARM1 in C9KO mice and controls under the fasted condition was much greater than that under normal conditions. Collectively, these data demonstrate that C9orf72 is a negative regulator of CARM1 protein level.
C9orf72 negatively regulates CARM1 via lysosomal degradation
To gain insight into the molecular mechanism underlying the C9orf72-mediated regulation of CARM1 protein level, we first determined the CARM1 mRNA levels. However, there was no difference in CARM1 mRNA levels between C9KO MEFs and wild-type cells under either well-fed or glucose starvation conditions (Supplemental Fig. S3C), suggesting that the regulation of CARM1 by C9orf72 did not occur at the transcriptional level. Next, we asked whether C9orf72 regulates the turnover of the CARM1 protein. We performed a cycloheximide chase analysis to measure the half-life of the CARM1 protein. In wild-type MEFs, the endogenous CARM1 protein half-life was ∼2 h under glucose starvation; however, its half-life was increased to ∼4 h in C9KO MEFs, indicating that the degradation of the CARM1 protein was significantly impaired in the absence of C9orf72 (Supplemental Fig. S3D).It was reported recently that CARM1 can be degraded by proteasomes and that the level of its E3 ubiquitin ligase, SKP2, is reduced under glucose starvation due to the activation of AMPK (Supplemental Fig. S3E), leading to CARM1 up-regulation (Shin et al. 2016). However, treatment with an AMPK-specific inhibitor, compound C, did not abolish the increase of CARM1 levels in C9KO MEFs under glucose starvation (Supplemental Fig. S3E). Additionally, there was no change detected in the SKP2 protein levels in C9KO MEFs and the brains of C9KO mice with or without starvation treatment (Supplemental Fig. S3F,G). Moreover, loss of C9orf72 did not affect the binding of CARM1 to SKP2 or the ubiquitination of CARM1 (Supplemental Fig. S3H,I). Thus, these data indicate that the C9orf72-dependent regulation of CARM1 is not mediated by AMPK/SKP2-dependent degradation through the ubiquitin–proteasome system.Aside from the ubiquitin–proteasome system, the autophagy–lysosome pathway is the other major avenue for protein degradation in eukaryotic cells. We therefore examined the possible role of lysosomes in the degradation of CARM1 protein. The blockage of lysosomal proteolysis by either bafilomycin A1 or chloroquine significantly increased the CARM1 protein levels under both well-fed and glucose-starved conditions but to a larger extent under starvation conditions (Fig. 4A,B). The inhibition of the lysosomal degradation activity was confirmed by the accumulation of the lysosomal marker LAMP1 (Fig. 4A). Similarly, blocking autophagy by depleting Atg5 or FIP200 significantly increased the CARM1 protein levels under glucose starvation conditions (Supplemental Fig. S3K–N). These results indicate that CARM1 is degraded at least partially via lysosomal proteolysis, especially under conditions of glucose starvation.
Figure 4.
CARM1 is degraded by the autophagy–lysosomal pathway. (A,B) MEFs growing under normal conditions or subjected to glucose starvation for 6 h were treated with 100 nM inhibitor of lysosomal degradation bafilomycin A1 or 25 µM chloroquine. The ratio of CARM1 or LAMP1 to β-actin was statistically analyzed. n = 3. (C) Lysosomes were isolated form MEFs and subjected to detection of CARM1 by immunoblotting. GAPDH (cytosol), PARP (nucleus), VDCA (mitochondria), and ERp72 (ER) were regarded as negative controls, and LAMP1 was regarded as a positive control. (D,E) MEFs were cultured in CM or starved with glucose-free medium for 6 h with or without the presence of 100 nM bafilomycin A1. The colocalization of CARM1 and LAMP1 was determined by immunostaining. The number of CARM1/LAMP1 double-positive puncta per cell was counted. Thirty to 40 cells in each group from three independent experiments were statistically analyzed. (GS) Glucose starvation. Data are presented as mean ± SEM. (*) P < 0.05.
CARM1 is degraded by the autophagy–lysosomal pathway. (A,B) MEFs growing under normal conditions or subjected to glucose starvation for 6 h were treated with 100 nM inhibitor of lysosomal degradation bafilomycin A1 or 25 µM chloroquine. The ratio of CARM1 or LAMP1 to β-actin was statistically analyzed. n = 3. (C) Lysosomes were isolated form MEFs and subjected to detection of CARM1 by immunoblotting. GAPDH (cytosol), PARP (nucleus), VDCA (mitochondria), and ERp72 (ER) were regarded as negative controls, and LAMP1 was regarded as a positive control. (D,E) MEFs were cultured in CM or starved with glucose-free medium for 6 h with or without the presence of 100 nM bafilomycin A1. The colocalization of CARM1 and LAMP1 was determined by immunostaining. The number of CARM1/LAMP1 double-positive puncta per cell was counted. Thirty to 40 cells in each group from three independent experiments were statistically analyzed. (GS) Glucose starvation. Data are presented as mean ± SEM. (*) P < 0.05.To further characterize the lysosome-mediated CARM1 degradation, we studied the subcellular distribution of CARM1 and lysosomes by immunostaining. In MEFs growing under the normal conditions, CARM1 exhibited a largely diffuse distribution, with a few puncta in the cytoplasm. The majority of CARM1-positive puncta was colocalized with the lysosomes marked by LAMP1 (Fig. 4D). Treatment of the MEFs with either bafilomycin A1 or glucose starvation significantly increased the number of CARM1-positive puncta and their colocalization with lysosomes in a synergistic manner (Fig. 4D,E), suggesting that the lysosomal localization of CARM1 is enhanced under the conditions of glucose deprivation or lysosomal inhibition. To confirm the localization of CARM1 to lysosomes, we isolated lysosomes from MEF cells grown in glucose-free medium. Consistent with the immunostaining data, CARM1 was enriched in the isolated lysosomes (Fig. 4C). These results suggest that CARM1 is recruited to the lysosome for degradation upon glucose starvation.To determine whether C9orf72 is required for the lysosomal degradation of CARM1, we isolated lysosomes from wild-type and C9KO MEFs and assessed their CARM1 protein. Under the normal conditions, the lysosomal CARM1 was already decreased in C9KO MEFs (Fig. 5A). Furthermore, the starvation-induced lysosomal accumulation of CARM1 was completely abolished in the absence of C9orf72 (Fig. 5A), indicating that C9orf72 is required for the lysosomal localization of CARM1. We further confirmed this finding by examining the colocalization of CARM1 and lysosomes. In contrast to wild-type MEFs, C9KO MEFs had fewer CARM1-positive puncta, and, more importantly, there was no colocalization of CARM1 and the lysosome in the absence of C9orf72 (Fig. 5B,C). Moreover, treatment of the MEFs with either glucose starvation or bafilomycin A1 failed to recruit CARM1 to the lysosome in the absence of C9orf72 (Fig. 5B,C), confirming that C9orf72 is essential for the localization of CARM1 to lysosomes. Additionally, blocking the autophagy–lysosome pathway by treatment with chemical inhibitor bafilomycin A1 or by genetic depletion of Atg5 or FIP200 failed to increase the CARM1 protein levels in C9KO MEFs, in contrast to wild-type MEFs, under glucose starvation (Supplemental Fig. S3J–N), indicating that the C9orf72-dependent degradation of CARM1 requires the autophagy–lysosome pathway.
Figure 5.
C9orf72 interacts with CARM1 and is required for its lysosomal degradation. (A) Wild-type and C9KO MEFs were grown with or without glucose starvation for 6 h. Lysosomes were isolated, and CARM1 protein levels were determined by immunoblotting. n = 3. (B,C) Wild-type and C9KO MEFs were grown with or without glucose starvation conditions for 6 h in the presence or absence of 100 nM bafilomycin A1, and then the colocalization of CARM1 and LAMP1 was determined by immunostaining. The number of CARM1/LAMP1 double-positive puncta per cell were counted. Forty to 60 cells in each group from three independent experiments were analyzed. (D,E) Wild-type and C9KO MEFs were treated with or without 20 µM MG132 for 4 h, and the CARM1 protein levels in the cytoplasmic and nuclear fractions were detected by immunoblotting. Wild-type and C9KO MEFs were starved with glucose-free medium for 6 h with or without 200 nM bafilomycin A1, and the CARM1 protein levels in the cytoplasmic and nuclear fractions were determined by immunoblotting. n = 3. (F) MEFs were grown with or without glucose starvation for 6 h followed by immunoprecipitation using anti-CARM1 antibody. IgG was used as a control. (G,H) Purified C9orf72 and Flag-CARM1 proteins were shown to have direct interaction using the in vitro protein–protein interaction assay. Flag-CARM1 was immunoprecipitated by Flag beads, and coimmunoprecipitated C9orf72 (arrowhead) was detected by Western blotting. Flag beads only and Flag peptides were used as controls. The asterisk indicates IgG common to all samples. n = 3. (I,J) C9orf2 long-form full-length protein (1–481), the short form (1–222), and the C-terminal fragment (149–481) were tagged with Flag and expressed in HEK293 cells, and their interaction with endogenous CARM1 was analyzed by coimmunoprecipitation assays. Immunoprecipitation was conducted using Flag beads after cells were starved with glucose-free medium for 16 h. GUS-Flag was used as a control. (K,L) MEFs were fed or starved for 6 h with or without 100 nM bafilomycin A1 treatment. Lysosomal localization of endogenous C9orf72 and CARM1 was determined by immunostaining. Twenty-six to 40 cells from three independent experiments were statistically analyzed. (M) MEFs were grown with glucose-free medium for 0, 6, and 16 h. Lysosomes were isolated, and CARM1 and C9orf72 protein levels were determined by immunoblotting. LAMP1 was used as a loading control. n = 3. Data are presented as mean ± SEM. (*) P < 0.05; (**) P < 0.01; (***) P < 0.001; (****) P < 0.0001.
C9orf72 interacts with CARM1 and is required for its lysosomal degradation. (A) Wild-type and C9KO MEFs were grown with or without glucose starvation for 6 h. Lysosomes were isolated, and CARM1 protein levels were determined by immunoblotting. n = 3. (B,C) Wild-type and C9KO MEFs were grown with or without glucose starvation conditions for 6 h in the presence or absence of 100 nM bafilomycin A1, and then the colocalization of CARM1 and LAMP1 was determined by immunostaining. The number of CARM1/LAMP1 double-positive puncta per cell were counted. Forty to 60 cells in each group from three independent experiments were analyzed. (D,E) Wild-type and C9KO MEFs were treated with or without 20 µM MG132 for 4 h, and the CARM1 protein levels in the cytoplasmic and nuclear fractions were detected by immunoblotting. Wild-type and C9KO MEFs were starved with glucose-free medium for 6 h with or without 200 nM bafilomycin A1, and the CARM1 protein levels in the cytoplasmic and nuclear fractions were determined by immunoblotting. n = 3. (F) MEFs were grown with or without glucose starvation for 6 h followed by immunoprecipitation using anti-CARM1 antibody. IgG was used as a control. (G,H) Purified C9orf72 and Flag-CARM1 proteins were shown to have direct interaction using the in vitro protein–protein interaction assay. Flag-CARM1 was immunoprecipitated by Flag beads, and coimmunoprecipitated C9orf72 (arrowhead) was detected by Western blotting. Flag beads only and Flag peptides were used as controls. The asterisk indicates IgG common to all samples. n = 3. (I,J) C9orf2 long-form full-length protein (1–481), the short form (1–222), and the C-terminal fragment (149–481) were tagged with Flag and expressed in HEK293 cells, and their interaction with endogenous CARM1 was analyzed by coimmunoprecipitation assays. Immunoprecipitation was conducted using Flag beads after cells were starved with glucose-free medium for 16 h. GUS-Flag was used as a control. (K,L) MEFs were fed or starved for 6 h with or without 100 nM bafilomycin A1 treatment. Lysosomal localization of endogenous C9orf72 and CARM1 was determined by immunostaining. Twenty-six to 40 cells from three independent experiments were statistically analyzed. (M) MEFs were grown with glucose-free medium for 0, 6, and 16 h. Lysosomes were isolated, and CARM1 and C9orf72 protein levels were determined by immunoblotting. LAMP1 was used as a loading control. n = 3. Data are presented as mean ± SEM. (*) P < 0.05; (**) P < 0.01; (***) P < 0.001; (****) P < 0.0001.Since our proteomic data suggest that CARM1 interacts with C9orf72 (Supplemental Table S1), we assessed whether C9orf72 recruits CARM1 to lysosomes for degradation through their interaction. To address this question, we examined C9orf72-dependent degradation of CARM1. First, in wild-type MEFs, treatment with the proteasome inhibitor MG132 resulted in accumulation of CARM1 only in the nucleus but not in the cytoplasm (Fig. 5D,E), consistent with the previously reported proteasomal degradation of nuclear CARM1 (Shin et al. 2016). However, treatment of wild-type MEFs with the lysosome inhibitor bafilomycin A1 significantly increased the protein levels of CARM1 in both cytoplasmic and nuclear compartments (Fig. 5D,E). This result indicates that the degradation of CARM1 in the cytoplasm is mediated mainly by the lysosome and that inhibition of the lysosomal degradation leads to accumulation of CARM1 in both the cytoplasm and the nucleus, which are two interconnected compartments. Furthermore, in C9KO MEFs, the MG132 treatment still led to accumulation of nuclear CARM1; however, the bafilomycin A1 treatment yielded no change of CARM1 levels in either the cytoplasm or the nucleus, indicating that C9orf72 is required for the lysosomal degradation of CARM1 (Fig. 5D,E).Next, we investigated the interaction between CARM1 and C9orf72. First, we confirmed the association of CARM1 with C9orf72 in HEK293 cells, where immunoprecipitation of CARM1 but not IgG control pulled down C9orf72 (Fig. 5F). Interestingly, glucose starvation substantially increased the association between CARM1 and C9orf72 (Fig. 5F). Furthermore, we demonstrated that CARM1 can directly interact with C9orf72 by coimmunoprecipitation assays using purified proteins (Fig. 5G,H; Supplemental Fig. S4C). Additionally, we examined the protein domains important for the interaction between CARM1 and C9orf72. CARM1 has a PH domain-like fold (residue 28–139) that is adjacent to the core catalytic domain (residues 140–479) (Troffer-Charlier et al. 2007). Consistent with a previous report (Troffer-Charlier et al. 2007), the remaining N-terminal (residues 1–27) and C-terminal (residues 480–608) regions are highly discorded and not stable enough to accumulate when expressed in the cells. The PH domain-like fold but not the core catalytic domain of CARM1 interacted with C9orf72, as indicated by coimmunoprecipitation assays (Supplemental Fig. S4D–F), suggesting that the PH domain-like fold of CARM1 contributes to the interaction with C9orf2. As a DENN-like protein, C9orf72 protein domains have not been clearly established. The major form of C9orf72 protein is 481 residues long, and a minor N-terminal short form (residues 1–222) is also expressed. Compared with the full-length C9orf2 protein (residues 1–481), the N-terminal short form (residues 1–222) and a relatively stable C-terminal truncate (residues 149–481) have less interaction with endogenous CARM1 in coimmunoprecipitation assays (Fig. 5I,J), suggesting that full-length C9orf72 is required for optimal interaction with CARM1.Next, we studied the colocalization of C9orf72, CARM1, and lysosome. Triple immunostaining indicated that both C9orf72 and CARM1 were colocalized with LAMP1, the marker for lysosomes, especially under glucose starvation or bafilomycin A1 treatment (Fig. K,L). We then analyzed the dynamic relocation of C9orf72 and CARM1 upon glucose starvation in purified lysosomal fractions. Both C9orf72 and CARM1 were detected in the isolated lysosomes, and their lysosomal recruitment was further enhanced by starvation in an identical time-dependent manner (Fig. 5M). Furthermore, inhibiting lysosomal degradation with bafilomycin A1 significantly increased the protein levels of CARM1 and C9orf72 (Fig. 4A; Supplemental Fig. S4A,B) as well as the colocalization of the two proteins with the lysosome (Fig. 5K,L), suggesting that both CARM1 and C9orf72 are degraded in lysosomes. Taken together, given that the loss of C9orf72 leads to increased levels of CARM1, these results suggest that C9orf72 is required for the lysosomal localization and degradation of CARM1, especially under the glucose starvation condition.
CARM1 is required for the regulation of lipid metabolism by C9orf72
Since CARM1 was negatively regulated by C9orf72 (Fig. 3; Supplemental Fig. S3A), we sought to test whether CARM1 mediates the dysfunctional lipid metabolism or the altered autophagy–lysosomal pathway in C9KO cells. CARM1 activity as a transcription coactivator depends on its translocation from the cytoplasm to the nucleus. To directly study the transport of CARM1 from the cytoplasm to the nucleus, we sought to identify the nuclear localization sequence (NLS) of the protein. Bioinformatic analysis predicted the region of residues 347–380 as a potential NLS for CARM1. To experimentally validate the NLS domain for CARM1, we expressed V5-tagged wild-type hCARM1 in MEFs and observed nuclear enrichment of CARM1 under glucose starvation conditions (Fig. 6A). By comparison, removing the region of residues 347–380 completely blocked the nuclear translocation of CARM1 in either wild-type or C9KO MEFs (Fig. 6A), establishing this sequence as the NLS for the protein. Next, we examined the subcellular localization of CARM1 in wild-type and C9KO MEFs. By immunostaining for endogenous CARM1, we found that the loss of C9orf72 led to a significant increase in the nuclear staining of CARM1, and this effect was more pronounced in conditions of glucose starvation (Fig. 6B). Consistent with this observation, C9KO MEFs exhibited a significantly higher level of CARM1 in the isolated nucleus than did wild-type MEFs under both well-fed and glucose-starved conditions (Fig. 6C). Similar results were also obtained in HEK293 cells in which C9orf72 was knocked down (Supplemental Fig. S3B). These data indicate that the loss of C9orf72 increases CARM1 protein levels and nuclear localization, suggesting an augmentation in CARM1 activity and function in the nucleus.
Figure 6.
CARM1 is required for the regulation of lipid metabolism by C9orf72. (A) Wild-type V5-CARM1 and mutant V5-CARM1(Δ347–380) were expressed in wild-type and C9KO MEFs under glucose starvation conditions for 6 h. Eleven to 12 fields of view containing 39–47 cells from three independent experiments were statistically analyzed. (B) Wild-type and C9KO MEFs were cultured in CM or starved with glucose-free medium for 6 h followed by immunostaining of endogenous CARM1. Fifteen to 18 fields of view in each group from three independent experiments were statistically analyzed for the nuclear enrichment of CARM1. (C) CARM1 protein levels were determined by immunoblotting of the nuclear fractions of wild-type and C9KO MEFs grown with or without glucose starvation conditions for 6 h. The ratio of CARM1 to PARP was calculated and statistically analyzed. n = 3. (D,E) LDs were stained with BODIPY493/503 after wild-type, C9KO, and C9orf72/CARM1 double-knockout MEFs were grown with glucose-free medium for 16 h. The loss of C9orf72 led to an accumulation of LDs, which was reversed by the deletion of CARM1. The number of LDs per cell was counted, and 40 cells in each group from three independent experiments were statistically analyzed. (F,G) Wild-type, C9KO, and C9orf72/CARM1 double-knockout MEFs were grown with glucose-free medium for 16 h followed by quantitation of lipid amounts and FFA levels in each group. n = 3. (H) Wild-type, C9KO, and C9orf72/CARM1 double-knockout MEFs were starved for 16 h. LDs were isolated and immunoblotted against anti-LC3. ADRP served as a loading control. (I) Wild-type, C9KO, and C9orf72/CARM1 double-knockout MEFs were cultured in glucose-free medium with [1,2-14C] acetate at the final concentration of 0.3 µCi for 6 h. The incorporation of [1,2-14C] in total lipids was measured by a scintillation counter. Counts per minute (CPM) were normalized to the total amount of protein. n = 3. (J) After starving wild-type, C9KO, and C9orf72/CARM1 double-knockout MEFs with glucose-free medium for 6 h, the levels of ACC in each group were determined by immunoblotting. (K) ACC mRNA level was determined by quantitative PCR (qPCR) after MEFs were grown with glucose-free medium for 6 h. n = 3. (L–N) Wild-type and C9KO MEFs were starved for 6 h. The enrichment of CARM1 and H3R17me2 on the promoter of Atg14, Map1lc3b, or ACC in each group was measured by ChIP-qPCR (chromatin immunoprecipitation [ChIP] combined with qPCR) using anti-CARM1 and anti-H3R17me2 antibodies, respectively. n = 3. (GS) Glucose starvation. Data are presented as mean ± SEM. (*) P < 0.05; (**) P < 0.01; (***) P < 0.001; (****) P < 0.0001.
CARM1 is required for the regulation of lipid metabolism by C9orf72. (A) Wild-type V5-CARM1 and mutant V5-CARM1(Δ347–380) were expressed in wild-type and C9KO MEFs under glucose starvation conditions for 6 h. Eleven to 12 fields of view containing 39–47 cells from three independent experiments were statistically analyzed. (B) Wild-type and C9KO MEFs were cultured in CM or starved with glucose-free medium for 6 h followed by immunostaining of endogenous CARM1. Fifteen to 18 fields of view in each group from three independent experiments were statistically analyzed for the nuclear enrichment of CARM1. (C) CARM1 protein levels were determined by immunoblotting of the nuclear fractions of wild-type and C9KO MEFs grown with or without glucose starvation conditions for 6 h. The ratio of CARM1 to PARP was calculated and statistically analyzed. n = 3. (D,E) LDs were stained with BODIPY493/503 after wild-type, C9KO, and C9orf72/CARM1 double-knockout MEFs were grown with glucose-free medium for 16 h. The loss of C9orf72 led to an accumulation of LDs, which was reversed by the deletion of CARM1. The number of LDs per cell was counted, and 40 cells in each group from three independent experiments were statistically analyzed. (F,G) Wild-type, C9KO, and C9orf72/CARM1 double-knockout MEFs were grown with glucose-free medium for 16 h followed by quantitation of lipid amounts and FFA levels in each group. n = 3. (H) Wild-type, C9KO, and C9orf72/CARM1 double-knockout MEFs were starved for 16 h. LDs were isolated and immunoblotted against anti-LC3. ADRP served as a loading control. (I) Wild-type, C9KO, and C9orf72/CARM1 double-knockout MEFs were cultured in glucose-free medium with [1,2-14C] acetate at the final concentration of 0.3 µCi for 6 h. The incorporation of [1,2-14C] in total lipids was measured by a scintillation counter. Counts per minute (CPM) were normalized to the total amount of protein. n = 3. (J) After starving wild-type, C9KO, and C9orf72/CARM1 double-knockout MEFs with glucose-free medium for 6 h, the levels of ACC in each group were determined by immunoblotting. (K) ACC mRNA level was determined by quantitative PCR (qPCR) after MEFs were grown with glucose-free medium for 6 h. n = 3. (L–N) Wild-type and C9KO MEFs were starved for 6 h. The enrichment of CARM1 and H3R17me2 on the promoter of Atg14, Map1lc3b, or ACC in each group was measured by ChIP-qPCR (chromatin immunoprecipitation [ChIP] combined with qPCR) using anti-CARM1 and anti-H3R17me2 antibodies, respectively. n = 3. (GS) Glucose starvation. Data are presented as mean ± SEM. (*) P < 0.05; (**) P < 0.01; (***) P < 0.001; (****) P < 0.0001.We then assessed whether the up-regulation of CARM1 mediated the dysfunction in lipid metabolism and the autophagy–lysosomal pathway caused by loss of C9orf72. By using CRISPR–Cas9 genome editing, we deleted CARM1 in C9KO MEFs to create double-knockout cells. In C9KO MEFs under glucose starvation conditions, the depletion of CARM1 completely reversed their abnormally high levels of lipids, LDs, and FFAs to normal levels (Fig. 6D–G), suggesting that CARM1 is a key factor downstream from C9orf72 in the regulation of lipid metabolism. As CARM1 is the coactivator of TFEB (Shin et al. 2016), which is an autophagy regulator that we found previously to translocate to the nucleus upon loss of C9orf2 (Ugolino et al. 2016), we investigated potential regulation of TFEB in these settings. Although TFEB translocated from the cytoplasm to the nucleus in C9KO MEFs compared with wild-type MEFs, the deletion of CARM1 in C9KO MEFs did not affect the nuclear enrichment of TFEB (Supplemental Fig. SA,B), suggesting that CARM1 does not regulate the nuclear transportation of TFEB.To examine the autophagy–lysosomal function, we analyzed the levels of LC3 proteins in wild-type MEFs, C9KO cells, and CARM1/C9orf72 double-knockout cells with or without the treatment with bafilomycin A1. Under glucose starvation conditions, the C9KO cells showed a much higher level of LC3II in the presence of bafilomycin A1, indicating that the loss of C9orf72 leads to an increase in the autophagic flux induced by glucose deprivation (Supplemental Fig. S5C,D). However, in the CARM1/C9orf72 double-knockout cells, bafilomycin treatment failed to accumulate LC3II under glucose starvation conditions, indicating that the increased autophagic flux were reversed (Supplemental Fig. S5C,D). Accordingly, the level of the lysosomal marker LAMP1 was also reduced in CARM1/C9orf72 double-knockout cells as compared with C9KO cells (Supplemental Fig. S5C,E), suggesting that the lysosomal function was dramatically decreased upon removal of CARM1. These data indicate that CARM1 is required for the enhanced autophagy–lysosomal function caused by loss of C9orf72.We next examined the role of CARM1 in C9orf72-regulated autophagic digestion of lipids. The isolated LDs from the C9KO cells exhibit increased LC3II levels after glucose deprivation (Figs. 2C, 6H). However, the CARM1/C9orf72 double-knockout cells showed a reduced LC3II level in the isolated LDs as compared with wild-type MEFs (Fig. 6H), suggesting that the autophagic digestion of LDs was decreased upon the loss of CARM1. Next, we analyzed the colocalization of LDs and lysosomes in wild-type MEFs, C9KO cells, and CARM1/C9orf72 double-knockout cells. As compared with the C9KO cells, which showed a significant increase in the colocalization of BODIPY-labeled LDs and LAMP1-labeled lysosomes under conditions of glucose starvation, the CARM1/C9orf72 double-knockout cells showed almost no colocalization of these two markers (Supplemental Fig. S5F,G). These data indicate that CARM1 is required for the enhanced lipid metabolism through autophagy that is induced by the loss of C9orf72.We further examined whether CARM1 is involved in the enhanced FA de novo synthesis in the absence of C9orf72 using radiolabeled [1,2-14C] acetate. As mentioned above, the FA de novo synthesis was enhanced in C9KO MEFs compared with wild-type controls under glucose starvation (Figs. 2G, 6I). However, the deletion of CARM1 in C9KO MEFs completely abolished the enhancement in the biosynthetic process, as CARM1/C9orf72 double-mutant MEFs presented an equal level of 14C incorporation in lipids with wild-type controls (Fig. 6I). Next, we asked whether CARM1 underlies the dysregulation of ACC, the rate-limiting enzyme of de novo FA synthesis that is up-regulated upon the loss of C9orf72 in glucose starvation (Fig. 2E,F). As compared with the C9KO MEFs under glucose starvation, the CARM1/C9orf72 double-knockout cells showed a normal level of ACC protein, similar to that in wild-type cells (Fig. 6J). Consistently, the mRNA levels of the mouse ACC changed in accordance with the protein levels (Fig. 6K), suggesting that CARM1 regulates ACC at the transcriptional level. These data suggest that CARM1 is required for the up-regulation of ACC and the increased de novo biogenesis of lipids resulting from the loss of C9orf72.CARM1 functions as a transcriptional coactivator and catalyzes the methylation on histone H3R17, which is associated with transcriptional activation (Yang and Bedford 2013; Shin et al. 2016). The enhanced autophagy and FFA de novo synthesis in the absence of C9orf72 could be controlled by the epigenetic regulation of CARM1 on specific genes. The epigenetic regulation of CARM1 on autophagic genes, including Atg14 and Map1lc3b, via the methylation on H3R17 has been established previously (Shin et al. 2016). Here we found that C9KO MEFs showed increased enrichment of CARM1 and H3R17me2 at the promoter regions of Atg14 and Map1lc3b under glucose starvation conditions when compared with wild-type MEFs (Fig. 6L,M). To explore whether the transcriptional activation of ACC is epigenetically regulated by CARM1 via the methylation on H3R17, we examined the level of H3R17me2 bound at the promoter region of the mouse gene encoding ACC. We first analyzed a chromatin immunoprecipitation (ChIP) sequencing (ChIP-seq) data set generated from MEFs in a previous study (Shin et al. 2016) and found that H3R17me2 was enriched at the mouse gene encoding ACC (Supplemental Fig. S6A). By the ChIP-qPCR (ChIP combined with quantitative PCR) assay, we confirmed that the methylated H3R17 was indeed highly enriched at the gene locus using an H3R17me2-specific antibody (Supplemental Fig. S6B). Furthermore, we found that H3R17me2 accumulated at a much higher level at the mouse ACC gene promoter in C9KO MEFs than wild-type MEFs under 6-h glucose starvation conditions (Fig. 6N; Supplemental Fig. S6C), indicating that loss of C9orf72 enriched H3R17me2 at the locus. Consistent with H3R17me2, CARM1 showed a threefold higher enrichment at the mouse ACC gene promoter in C9KO MEFs compared with wild-type MEFs under glucose starvation for 6 h (Fig. 6N; Supplemental Fig. S6C). These data suggest that the enhanced association of CARM1 and H3R17me2 with the ACC promoter region mediates the increased transcriptional activation of the ACC gene in the absence of C9orf72.
Dysregulation of CARM1 and lipid metabolism in patients with C9orf72-linked ALS/FTD
The most common cause of ALS and FTD is the hexanucleotide repeat expansion in C9orf72 (DeJesus-Hernandez et al. 2011; Renton et al. 2011). One consequence of the repeat expansion is a reduction in the level of the C9orf72 protein (DeJesus-Hernandez et al. 2011; Gijselinck et al. 2012; Belzil et al. 2013; Ciura et al. 2013; Donnelly et al. 2013; Mori et al. 2013; Xi et al. 2013; Liu et al. 2014; Waite et al. 2014). Therefore, we determined whether CARM1 is dysregulated in C9orf72-linked ALS/FTD patients. First, we confirmed that the C9orf72 protein levels were reduced in two independent lines of B lymphocytes from ALS patients carrying the C9orf72 repeat expansion as compared with two controls (Fig. 7A,B). We found that the two patient-derived B lymphocyte lines exhibited higher levels of CARM1 protein than did controls, especially under glucose starvation conditions (Fig. 7C,D). Consistent with the observation in lymphocytes, we also found up-regulated CARM1 protein in the induced pluripotent stem cell (iPSC)-derived motor neurons from two C9orf72-linked ALS/FTD patients when compared with two non-ALS/FTD controls (Fig. 7K,O). Furthermore, we validated the up-regulation of CARM1 in the spinal cord tissues of three C9orf72-linked ALS/FTD patients, which is in accordance with reduced C9orf72 protein levels observed in the patients’ tissues (Fig. 7F–I).
Figure 7.
Dysfunctional lipid metabolism and dysregulation of CARM1 in C9orf72-linked ALS patients. (A,B) C9orf72 protein levels in B lymphocytes derived from C9orf72-linked ALS patients and controls were determined by immunoblotting. n = 4. (C,D) C9 ALS patient and control B lymphocytes were cultured in CM or glucose-free medium for 6 h, and C9orf72 protein levels were determined as in A and B. n = 4. (E) FFA levels were determined in two independent pairs of iPSC-derived motor neurons from control and C9 ALS patients. n = 3. (F–J) Protein levels of C9orf72, CARM1, and LAMP1 in spinal cords from three C9 ALS patients and four controls were determined by immunoblotting. n = 3–4. (K) Representative immunoblots for analyzing CARM1, C9orf72, ACC, and LAMP1 in iPSC-derived motor neurons from two C9 ALS patients and two controls. (L) Representative images of iPSC-derived motor neurons from two C9 ALS patients and two controls, including the staining with CHAT (motor neuron marker), BODIPY (LD), and LAMP1 (lysosomal marker). (M,N) Quantitative analyses of BODIPY staining (n = 24–27 fields of view; K) and BODIPY/LAMP1 dual-positive puncta (45–47 cells; L) in iPSC-derived motor neurons from C9 ALS patients and controls. (O–S) Quantitation of the immunoblotting analysis in I for iPSC-derived motor neurons from C9 ALS patients and controls. n = 4. (GS) Glucose starvation. Data are presented as mean ± SEM. (*) P < 0.05; (**) P < 0.01; (***) P < 0.001.
Dysfunctional lipid metabolism and dysregulation of CARM1 in C9orf72-linked ALS patients. (A,B) C9orf72 protein levels in B lymphocytes derived from C9orf72-linked ALS patients and controls were determined by immunoblotting. n = 4. (C,D) C9 ALSpatient and control B lymphocytes were cultured in CM or glucose-free medium for 6 h, and C9orf72 protein levels were determined as in A and B. n = 4. (E) FFA levels were determined in two independent pairs of iPSC-derived motor neurons from control and C9 ALS patients. n = 3. (F–J) Protein levels of C9orf72, CARM1, and LAMP1 in spinal cords from three C9 ALS patients and four controls were determined by immunoblotting. n = 3–4. (K) Representative immunoblots for analyzing CARM1, C9orf72, ACC, and LAMP1 in iPSC-derived motor neurons from two C9 ALS patients and two controls. (L) Representative images of iPSC-derived motor neurons from two C9 ALS patients and two controls, including the staining with CHAT (motor neuron marker), BODIPY (LD), and LAMP1 (lysosomal marker). (M,N) Quantitative analyses of BODIPY staining (n = 24–27 fields of view; K) and BODIPY/LAMP1 dual-positive puncta (45–47 cells; L) in iPSC-derived motor neurons from C9 ALS patients and controls. (O–S) Quantitation of the immunoblotting analysis in I for iPSC-derived motor neurons from C9 ALS patients and controls. n = 4. (GS) Glucose starvation. Data are presented as mean ± SEM. (*) P < 0.05; (**) P < 0.01; (***) P < 0.001.Next, we examined the lipid metabolism, including the levels of FFA and LDs in the iPSC-derived motor neurons from patients with C9orf72-linked ALS/FTD. We found that the levels of FFA and LDs in the two independent lines of motor neurons from C9orf72ALS/FTD patients were higher than those in controls (Fig. 7E,L,M), indicating a dysfunctional lipid metabolism in the patient-derived neurons. Moreover, the lysosomal marker LAMP1 protein levels were increased in the C9orf72ALS/FTDpatient-derived motor neurons and spinal cord tissues (Fig. 7F,I,K,R). Additionally, the colocalization of LDs and lysosomes was increased in the C9orf72ALS/FTDpatient-derived motor neurons (Fig. 7L,N), suggesting up-regulated digestion of LDs via the autophagy–lysosome pathway after loss of C9orf72. Furthermore, the C9orf72ALS/FTDpatient-derived motor neurons showed an increased protein level of ACC (Fig. 7K,Q), consistent with the up-regulation of the de novo FA synthesis as a result of increased CARM1 activity in the patients’ cells. Last, in agreement with the up-regulation of NOX2 in C9KO MEFs (Fig. 2H,J), which is induced by the increased FFA levels, the NOX2 protein was up-regulated in the C9orf72ALS/FTDpatient-derived motor neurons (Fig. 7K,S) and spinal cord tissues (Fig. 7F,J). Taken together, these data indicate that the pathways related to CARM1 and lipid metabolism are dysregulated in C9orf72ALS/FTDpatient cells and tissues.
Discussion
In the present study, we identified a function for C9orf72 mediated by CARM1 in regulating lipid metabolism. This newly identified activity represents a previously unknown pathway in regulating lipid mobilization under nutrient stress induced by glucose starvation in the cell. Our findings also implicate this pathway in the pathogenesis of C9orf72-linked ALS/FTD, as suggested by the dysregulation of CARM1 in patient-derived cells and tissues. The molecular connections highlight a dynamic regulation of lipid metabolism, autophagy, and transcriptional programs. Collectively, C9orf72 emerges as a regulator of lipid metabolism and autophagy in the maintenance of metabolic homeostasis, particularly during changes in nutrient availability (Supplemental Fig. S7).DENN-like proteins have been reported to carry out functions related to membrane trafficking and autophagy (Marat et al. 2011). Our findings indicate that C9orf72, as a DENN-like protein, functions in regulating lipid homeostasis. C9orf72 is identified as a negative regulator of CARM1, which is required for the regulation of lipid metabolism by C9orf72. Under conditions of glucose starvation, CARM1 is translocated from the cytoplasm to the nucleus, where it may act as an epigenetic regulator to activate the transcriptional program for the de novo lipogenesis and the autophagy–lysosome pathway as a stress response mechanism to maintain energy balance in the cell. In this starvation-induced adaptive program, autophagy plays a key role in the digestion of lipids as a nutrient source as well as in the biogenesis of LDs to replenish lipid storage. C9orf72 seems to play the role of a brake in this stress response by recruiting CARM1 to lysosomes for degradation, providing a mechanism for controlling starvation-induced lipid utilization. Thus, a reduction in C9orf72 function leads to aberrant activation of lipid metabolism. In ALS patients, the down-regulation of C9orf72 and up-regulation of CARM1 in the central nervous system suggest that dysregulation of lipid metabolism could contribute to the pathogenesis of the disease.Autophagy, a common pathway implicated in neurodegenerative diseases (Nixon 2013; Yamamoto and Yue 2014), is an important regulator of lipid metabolism, especially under starvation conditions, since the energy metabolism shifts to the breakdown of lipids under these conditions (Singh et al. 2009; Settembre et al. 2013; Kaushik and Cuervo 2015). We found that the loss of C9orf72 increased the autophagic flux and its association with LDs under glucose starvation conditions (Fig. 2A–F; Supplemental Fig. S2B–F). In addition to autophagy as a mechanism for supplying the FFAs needed for LD biogenesis, the de novo synthesis of FAs was enhanced by the loss of C9orf72 (Fig. 2G). This enhancement of FA synthesis resulted at least in part from the up-regulation of the rate-limiting enzyme ACC, which promotes the FA synthesis, in the absence of C9orf72 after prolonged glucose starvation (Fig. 2H,I). These results are consistent with the increase in FFA levels seen with the loss of C9orf72. The increase in lipogenesis and autophagy that occurs when C9orf72 activity is lost is in line with the activation of CARM1, which mediates the transcriptional programs promoting autophagic functions and lipid metabolism. For instance, our data demonstrate that loss of C9orf72 promotes the nuclear enrichment of CARM1 and increases the activity of CARM1 as an epigenetic activator to be associated with the promoter region of the genes, including ACC, Atg14, and Map1lc3b (Fig. 6). It has also been reported that CARM1 activates transcription factor TFEB (Shin et al. 2016), which controls expression of autophagic and lysosomal gene expression (Settembre et al. 2011) and was found to be inactivated by C9orf72 (Ugolino et al. 2016), consistent with our findings here that C9orf72 interacts with and negatively regulates the turnover of CARM1 (Fig. 3; Supplemental Fig. S3A). Together, the identification of the C9orf92–CARM1 axis provides a molecular mechanism for the changes in autophagy and lipid metabolism upon loss of C9orf72.Our results indicate that loss of C9orf72 leads to cellular hypermetabolism of lipids. This mobilization of lipid metabolism is an adaptive response to nutrient stresses such as glucose starvation. C9orf72 appears to offer a control mechanism built in by nature to buffer the stress response. However, when C9orf72 function is reduced, such as in patients’ cells, a chronic stress state is mimicked, or the adaptive response is prone to overdrive, which may contribute to the susceptibility of the cells to undergo degeneration. This metabolic imbalance of energy and lipids could be particularly relevant to the pathogenesis of ALS/FTD, which is associated with hypermetabolism and hyperlipidemia. We found that NOX2, which is associated with increased FFAs and promotes oxidative stress (Inoguchi et al. 2000), was up-regulated in C9orf72ALS/FTDpatient cells and tissues, suggestive of functional alterations as a result of the dysregulated lipid metabolism. NOX2 has also been found to be up-regulated in ALS-linked SOD1 mouse models and sporadic ALS patients and may participate in the pathogenesis (Wu et al. 2006; Marden et al. 2007). There is also other evidence suggesting that a dysregulation of lipid metabolism is associated with motor neuron diseases. For example, the abnormal up-regulation of CARM1, which was observed in ALS/FTD patients in the present study, has also been found in animal models and cells of patients with spinal muscular atrophy (Sanchez et al. 2013). Moreover, mutations in Spartin/SPG20, a gene important for LD turnover, have been linked to hereditary spastic paraplegia (Patel et al. 2002; Eastman et al. 2009). In summary, our identification of the C9orf72–CARM1 signaling cascade that is involved in regulating lipid metabolism may shed light on the pathogenic mechanisms of ALS/FTD and other related diseases.
Materials and methods
Plasmids
The C9orf72 shRNAs were constructed as described previously (Ugolino et al. 2016). The FIP200 shRNA was purchased from Sigma (TRCN0000304384). The guide RNAs (gRNAs) for CRISPR–Cas9-mediated knockout of CARM1 or Atg5 were designed with Benchling as follows: CARM1 (oligo1: 5′-CACCGCTCACTATCGGCGACGCGAA-3′; oligo2: 5′-AAACTTCGCGTCGCCGATAGTGAGC-3′) and atg5 (oligo1: 5′-CACCGAAGAGTCAGCTATTTGACGT-3′; oligo2: 5′-AAACACGTCAAATAGCTGACTCTTC-3′). The oligos were synthesized and cloned into LentiCRISPRv2 plasmid (Sanjana et al. 2014). The Flag-tagged C9orf72 constructs were generated using the Gateway cloning system (Thermo Fisher) as described previously (Ugolino et al. 2016). For the expression of humanC9orf72 in C9KO MEFs, the humanC9orf72 cDNA was cloned into the pLenti-CMV-Puro-DEST(w118-1) vector using the Gateway cloning system (Thermo Fisher). HumanCARM1 cDNA (NM_199141.1) was generated from human B lymphocytes and cloned into the pcDNA3.1 plasmid with an N-terminal V5 tag using the Gateway cloning system. The NLS of CARM1 (residues 347–380) was predicated by the cNLS Mapper (Kosugi et al. 2009).
Cell culture
MEFs and HEK293 cells were maintained in DMEM supplemented with 10% FBS. Human B lymphocytes were from Coriell Cell Repositories and cultured with RPMI 1640 medium containing 15% FBS. The generation of C9KO MEFs from C9KO mouse embryos was described previously (Ugolino et al. 2016). For glucose starvation, cells were cultured with fresh CM for 2 h and then replaced with glucose-free DMEM containing 10% dialyzed FBS. For autophagic flux determination, cells were subjected to glucose starvation with or without 100 nM autophagy inhibitor bafilomycin A1 for 6 and 16 h. For the ubiquitination assay of CARM1, MEFs were treated with 10 µM MG132 for 4 h under glucose starvation. Lipofectamine 2000 reagent (Thermo Fisher) was used to perform cell transfection on HEK293 cells, and jetPRIME (Polyplus Transfection) was used on MEFs. To generate stable C9orf72 knockdown HEK293 cells, the plasmids encoding shRNAs that are either targeting C9orf72 or scrambled controls were transfected into HEK293 cells. Eight hours after transfection, cells were washed twice with PBS and cultured with fresh CM and then subjected to 2 µg/mL puromycin selection for 2 wk. Lentivirus was used to generate knockout and knockdown MEFs. For the preparation of lentivirus, HEK293 cells were cotransfected with the lentiviral plasmid and viral packaging vectors (psPAX2 and pMD2G). Sixty hours after transfection, cell supernatants were collected and passed through 0.45-µm cellulose acetate filters. For lentivirus infection of MEFs, cells were plated at 2 × 106 cells per 10-cm dish and then supplemented with either humanC9orf72-expressing lentivirus, CARM1 gRNA-expressing lentivirus, or FIP200 shRNA-expressing lentivirus for 48 h prior to puromycin selection at a final concentration of 5 µg/mL for additional 72 h. Cells stably expressing shRNA were maintained in 10% FBS DMEM containing puromycin at a final concentration of 2 µg/mL. Stable MEF lines expressing C9orf72 were generated by multiple rounds of puromycin selection. CARM1 knockout MEF lines were selected by picking individual colonies that exhibited no CARM1 expression.
Quantitative MS
For TMT-labeling quantitative MS, cells were washed with PBS and resuspended in lysis buffer (8 M urea/50 mM tetraethyl ammoniumbicarbonate). The lysates were diluted to a final urea concentration of 1 M, and trypsin/LysC (1:50 enzyme:protein; Promega) was added. After overnight incubation, peptides were sequentially acidified, destalted, and lyophilized. Peptides were resolved in 0.2% formic acid and then quantified. Peptides were then lyophilized and labeled by 6-plex TMT (Pierce TMT). Labeled peptides were mixed and desalted consequently. The labeled peptides were enriched in tandem for modified peptides, and then all modified peptides were desalted and resuspended for liquid chromatography-tandem MS (LC-MS/MS) analysis. Unmodified peptides were fragmented by basic pH reversed phase LC (RPLC) and then lyophilized and resolved for LC-MS/MS analysis. The resulting spectra were analyzed by Proteome Discoverer 2.1 (database used: mouse RefSeq version 78). Carbamidomethylation on cysteine residues and TMT on Lys and peptide N terminus were included as fixed modifications. Oxidation on methionine was included as dynamic modification for total protein. Up to two missed cleavages were allowed. A 1% false discovery rate was applied for both peptide and protein levels.According to the UniProt database, 604 mouse proteins are related to lipid metabolism. Among the 604 proteins, 214 proteins were identified in our quantitative proteomic data. Ratios of C9KO (glucose starvation)/C9KO (CM) and wild-type (glucose starvation)/wild-type (CM) were calculated, which reflect the extent of protein variation induced by glucose starvation in C9KO MEFs and wild-type MEFs, respectively. The comparison of these ratios was then used to evaluate whether glucose starvation affects wild-type MEFs and C9KO MEFs differently. By comparing the proteomic data with the UniProt database, the enrichment analysis on lipid synthesis and ER was tested using the Fisher test.For the SILAC quantitative MS, HEK293 cells were incubated with heavy (13C6,15N4 L-arginine, 13C6,15N2 L-lysine) or light (12C6,14N4 L-arginine, 12C6,14N2 L-lysine) DMEM. After the incubation, cells were verified for near completion of labeling by MS. After heavy isotope-labeled cells were transfected with C9orf72-Flag and light isotope-labeled cells were transfected with Lipofectamine, cells were lysed and precipitated with Flag tag beads. The immunoprecipitates were then pooled, concentrated, separated via SDS-PAGE, and subjected to trypsin in-gel digestion. The prepared samples were analyzed by a LC-MS/MS on an Orbitrap Elite mass spectrometer coupled with Easy nLC II LC system. Using the Proteome Discoverer 1.4 software suite against human RefSeq 59 protein database, the MS data were analyzed with the applications of 1% peptide spectrum match and peptide-level false discovery rate.
The quantification of lipids and FFAs
Total lipids were extracted using an organic extraction method. Briefly, 2 × 106 MEFs were collected by trypsinization, pelleted, and suspended in 100 µL of PBS. Cell homogenates were mixed with an organic alcohol solvent provided by Cell Biolabs (STA-612-T). The mixture was centrifuged to gravitationally separate the phases. The upper organic phases that contained lipids were collected. The extracted lipids were completely dried with a vacuum drier and then quantified for total lipids (neutral lipids; Cell Biolabs, STA-617) and FFAs (Millipore Sigma, MAK044). The fluorescence intensity of lipid samples was measured by a fluorescent plate reader (FFA: λex = 535/λem = 587 nm; lipid: λex = 490/λem = 585 nm) (BioTek, Synergy H1).
Cellular FA uptake
The FA uptake of MEFs was measured using a dodecanoic acid fluorescent FA substrate (Millipore Sigma, MAK156-1KT). Briefly, 2 × 104 MEFs were placed into each well of the 96-well plate, cultured in glucose-free medium for 4 h, and then incubated with serum- and glucose-free medium for 1 h. One-hundred microliters of TF2-C12 FA solution was added to each well, and the uptake of the substrates into cells, which results in an increase in fluorescence intensity, was read by a plate reader (λex = 485/λem = 515 nm) (BioTek, Synergy H1) in 10-min intervals for 30 min.
FA de novo synthesis
The FA de novo synthesis was measured using [1,2-14C] acetate as described previously with modifications (Lee et al. 2015). Specifically, MEFs were cultured with CM or glucose-free medium supplied with 0.3 µCi [1,2-14C] acetate for 6 h. Lipids were extracted by organic extraction and centrifuge phase separation followed by drying and resuspension (Cell Biolabs STA-612-T). The incorporation of [14C] into lipids was used to measure the de novo synthesis of FAs, which was quantified with a Beckman LS6500 scintillation counter. The radioactivity counts were normalized against protein input levels.
Subcellular fractionation
The cytosolic and nuclear fractions were extracted using a subcellular fractionation kit for cultured cells (Thermo Fisher, 78840). Cytoplasmic and membrane proteins were combined as the cytosolic fraction, and the nuclear-soluble and chromatin-bound proteins were combined as the nuclear fraction.For isolating lysosomes and LDs, wild-type and C9KO MEFs were cultured in complete culture medium or starved with glucose-free medium for 6 h. After washing with cold PBS twice, 3 × 107 MEFs from each group were harvested for lysosome isolation. The lysosome collection was prepared by gradient centrifugation using the lysosome enrichment kit for tissues and cultured cells (Thermo Fisher, 89839).LDs were purified as described previously with some modifications (Ding et al. 2013). Briefly, 1 × 108 cells were harvested and pelleted after being washed with cold PBS three times. Cell pellets were suspended in buffer A (20 mM tricine, 250 mM sucrose, 0.2 mM PMSF at pH 7.8) and kept for 20 min on ice. The suspensions were then passed through a 27 gauge, 1 in needle five to 10 times, while the lysis efficiency was monitored under a microscope. Cell suspensions were centrifuged at 3000g for 10 min at 4°C. Supernatants were moved into a tube, and 2 mL of buffer B (20 mM HEPES, 100 mM KCl, 2 mM MgCl2 at pH 7.4) was added carefully on top of the supernatants. After centrifugation at 182,000g for 1 h at 4°C, floating LDs at the top band of the gradient were carefully collected. The collected LDs were washed by centrifugation at 20,000g for 5 min at 4°C and then resuspended in 1 mL of buffer B. After centrifugation at 270,000g for 10 min at 4°C, supernatants were discarded, and the pellets were collected.
SDS-PAGE and Western blotting
All cells were briefly rinsed with cold PBS prior to collection. Both whole cells and subcellular fractions were lysed in RIPA buffer (50 mM Tris at pH 7.5, 150 mM NaCl, 0.5% SDS, 0.5% sarkosyl, 0.5% NP40, 20 mM EDTA, Roche protease inhibitors, 1 mM PMSF) on ice. Protein concentrations of lysates were determined by the bicinchonic acid assay (Thermo Fisher) before being analyzed by SDS-PAGE. The primary antibodies used included anti-CARM1 (Cell Signaling Technology, 3379), anti-skp2 (Santa Cruz Biotechnology, sc-7164), anti-LC3B (Cell Signaling Technology, 3868), anti-LAMP1 (Cell Signaling Technology, 3243), anti-C9orf72 (Bio-Rad VMA00065), anti-PARP (Cell Signaling Technology, 9542), anti-β-actin (Santa Cruz Biotechnology, sc-47778), anti-NOX2 (Abcam, ab129068), anti-ubiquitin (Cell Signaling Technology, 3936), anti-calnexin (Cell Signaling Technology, 2679P), anti-ACC (Cell Signaling Technology, 3676), and anti-ADRP (Progen Biotechnik, GP42).
Immunoprecipitation
Cells were lysed in immunoprecipitation lysis buffer (20 mM Tris-HCl at pH 7.5, 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na3VO4, 1 µg/mL leupeptin, cocktail, 1 mM PMSF) on ice, sonicated for 15 min on ice, and centrifuged at 14,000g for 10 min. The resulting supernatants were collected for protein concentration assay and immunoprecipitation. The supernatants were incubated with a specific primary antibody overnight at 4°C with gentle rotation. The mixture was then incubated with protein A magnetic beads for 2 h at 4°C with gentle rotation. For the Flag immunoprecipitation, the supernatants were directly incubated with Flag beads for 2 h at 4°C with gentle rotation. After the incubation, beads were precipitated, and liquids were discarded. After washing with immunoprecipitation lysis buffer five times, beads were incubated in IgG elution buffer (pH 2; Thermo Fisher) for 15 min at room temperature. The liquids were collected and boiled with SDS loading buffer before being analyzed by SDS-PAGE and immunoblotted.
Protein purification and in vitro protein–protein interaction assay
C9orf72-coding sequence fused to C-terminal of 6xHis-SUMO tag was cloned into the pSATL vector and transformed into ArcticExpress (DE3) cells (Agilent Technologies). Transformed cells were grown, harvested, and then resuspended in lysis buffer [20 mM Tris-HCl at pH 8.0, 250 mM NaCl, 100 mM glycine, 1 mM tris(2-carboxyethyl)phosphine (TCEP)] supplemented with 10 mM imidazole, 1 M urea, 1 mM ATP, 1 mM MgCl2, and 1× bestatin, pepstatin A, E-64, and phenylmethylsulfonyl fluoride followed by disruption with a French press. After centrifugation at 16,000g for 20 min at 4°C, the supernatant was loaded to an immobilized metal affinity chromatography (IMAC) column (Bio-Rad) charged with nickel sulfate followed by consecutive washes with lysis buffer, lysis buffer containing 1 M NaCl and lysis buffer containing 75 mM NaCl. C9orf72 protein was then eluted by 250 mM imidazole containing-lysis buffer and desalted with 75 mM NaCl-containing lysis buffer. The resulting protein was then incubated with 6xHis-tagged SUMO-specific protease (SENP) for 1.5 h at 4°C followed by a reverse nickel column purification. The resulting protein was then loaded on a HiTrap Q HP column (GE Healthcare) followed by a HiLoad 26/60 S200 size exclusion column (GE Healthcare) to pool clean fractions with free C9orf72 proteins. For the in vitro protein–protein interaction assay, 2 µg of purified proteins of C9orf72 was mixed with 2 µg of Flag-CARM1 (Active Motif, 81107) in 50 µL of reaction buffer (50 mM Tris-HCl at pH 8, 1% NP40, 150 mM NaCl) and rotated overnight at 4°C. Immunoprecipitation was conducted using Flag beads. C9orf72 pulled down by Flag-CARM1 was analyzed and quantified via SDS-PAGE and immunoblotting. Flag beads only and Flag peptides were used as controls.
Immunofluorescence
Cells were washed three times with PBS and then fixed in 4% paraformaldehyde in PBS for 15 min at room temperature. Fixed cells were permeabilized with 0.3% Triton X-100 and blocked in blocking buffer (1× PBS/5% normal serum/0.1% Towen-20) for 1 h at room temperature. Cells were incubated with primary antibodies overnight at 4°C. After washing three times with PBS, cells were incubated with fluorescently conjugated secondary antibodies for 2 h at room temperature. Cells were again washed three times with PBS and then visualized with an SP8 confocal microscope (Leica). For visualizing LDs, fixed cells were incubated with BODIPY493/503 dye (Invitrogen) at a dilution of 1:1000 for 30 min at room temperature. Primary antibodies applied for the immunofluorescent staining included anti-CARM1 (Cell Signaling Technology, 3379 and 12495; NOVUS, AF7277), anti-C9orf72 (Proteintech Group, 22637-1-AP), anti-LAMP1 (Cell Signaling Technology, 9091 and 15665), anti-calnexin (Cell Signaling Technology, 2679P), and anti-choline acetyltransferase (Millipore, NG1780580). LDs were analyzed by counting positive puncta per cell. Colocalization was analyzed by Pearson's R-value using Coloc 2 in ImageJ software or by counting double-positive puncta per cell.
Quantitative RT-qPCR
Total RNAs were extracted using the RNeasy Plus minikit (Qiagen, 74136), and cDNAs were synthesized using the QuantiTect reverse transcription kit (Qiagen, 205313). RT-qPCR was performed on a Bio-Rad thermal cycler with iQ SYBR Green PCR mix (Bio-Rad). The quantity of mRNA was calculated by the ΔΔCt method, and GAPDH was used as a control. All reactions were performed in triplicate. The following primers were used: human GAPDH (fwd, 5′-AAGGTGAAGGTCGGAGTCAAC-3′; rev, 5′-GGGGTCATTGATGGCAACAATA-3′), humanCARM1 (fwd, 5′-TCGCCACACCCAACGATTT-3′; rev, 5′-GTACTGCACGGCAGAAGACT-3′), mouse GAPDH (fwd, 5′-AAGGTCATCCCAGAGCTGAA-3′; rev, 5′-CTGCTTCACCACCTTCTTGA-3′), mouse CARM1 (fwd, 5′-ATGAGCACGGGCATTGTCCAAG-3′; rev 5′-TTGACTGCATAGTGGGCACTGG-3′), and the mouse homolog of ACC (fwd, 5′-ATGGGCGGAATGGTCTCTTTC-3′; rev, 5′-TGGGGACCTTGTCTTCATCAT-3′).
ChIP-qPCR and ChIP-seq analysis
MEFs (2 × 107) were cross-linked using 1% formaldehyde for 10 min at room temperature and quenched with glycine at a final concentration of 125 mM for 5 min. Cells were lysed in ChIP lysis buffer (50 mM HEPES-KOH at pH 7.5, 140 mM NaCl, 1 mM EDTA at pH 8, 0.1% sodium deoxycholate, 0.1% sodium deoxycholate, protease inhibitors). Lysates were sonicated to shear DNA to an average fragment size of 200–500 base pairs (bp) and centrifuged at 8000g for 10 min at 4°C. Supernatants were diluted 10 times with dilution buffer (50 mM Tris-HCl at pH 8, 150 mM NaCl, 2 mM EDTA at pH 8, 1% NP40, 0.5% sodium deoxycholate, protease inhibitors) and incubated with anti-CARM1 (Cell Signaling Technology, 12495) or anti-H3R17me2 (Abcam, ab8284) for 1 h at 4°C. The mixed samples were immunoprecipitated overnight at 4°C with 60 µL of protein A/G beads, which were blocked with 75 ng of single-stranded herring sperm DNA per microliter of beads and 0.1 µg of BSA per microliter of beads. After immunoprecipitation, beads were washed with low-salt wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 2 mM EDTA, 150 mM NaCl), high-salt wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 2 mM EDTA, 500 mM NaCl), LiCl buffer (0.25 M LiCl, 0.25 M LiCl, 1% sodium deoxycholate, 1 mM EDTA, 10 mM Tris-HCl at pH 8.0), and TE buffer (10 mM Tris at pH 8.0, 1 mM EDTA) and eluted in elution buffer (1% SDS, 100 mM NaHCO3). The supernatants were decross-linked and digested by adding 2 µL of RNase A and incubated overnight at 65°C with shaking. Samples were then digested with proteinase K for 1 h at 60°C. ChIP and input DNAs were purified, and qRT–PCR was applied to measure the enrichment of bound DNAs. The primers targeting the promoter region of the mouse gene encoding ACC (NCBI 107476: Acaca) were designed according to previously reported ChIP-seq data (Shin et al. 2016). The following primers were used: primer set 1 (fwd, 5′-ATCTAATAACCTGGCCTTCA-3′; rev, 5′-GGTTCTCCTATCCGCTAA-3′), primer set 2 (fwd, 5′-CGGAACCTGGGAGGAGTA-3′; rev, 5′-AGGGCAGAATCTCCACTCACAT-3′), Atg14 (fwd, 5′-GAGACGCCATGATGATCTGA-3′; rev, 5′-GCCAAGGAGTGTGGGAAGTA-3′), and Map1lc3b (fwd, 5′-AGCCAGTGGGATATTGGTCT-3′; rev, 5′-AG AGCCTGCGGTACCCTAC-3′). The qPCR data were normalized against the input and the IgG controls. The data sets for H3R17me2 ChIP-seq were acquired from the NCBI Gene Expression Omnibus (GEO) database (GSE72901) (Shin et al. 2016) and uploaded to the Galaxy Web platform (Afgan et al. 2016) for analysis. Reads were aligned to the mouse genome (mm9) using Bowtie2. Only uniquely mapped reads were retained, and duplicate reads with mapping quality <20 were filtered out using SAMtools. The H3R17me2 peaks were identified using MACS2 with optimal parameters (q-value < 0.05, extension size: 141 bp) obtained from the MACS2 predicted tool. The read coverage distribution and predicted peaks at the locus were displayed in Integrative Genomics Viewer (IGV) browser.
Animal studies
The C9KO mice were generated in our previous study (Ugolino et al. 2016). The animal protocol was approved by the Johns Hopkins Animal Care and Use Committee following the National Research Council's guidance of the Care and Use of Laboratory Animals. Wild-type and C9KO mice were fed or fasted for 24 h. The brains were then isolated, and the cortex tissue lysate was prepared for Western blotting analysis. The mouse tissues were lysed in modified RIPA buffer (50 mM Tris at pH 7.5, 150 mM NaCl, 1% NP40, 0.1% SDS, 100 mM NaF, 17.5 mM β-glycerophosphate, 2.5% sodium deoxycholate, 10% glycerol, 1 mM PMSF, cocktail). Samples were sonicated and then centrifuged at 12,000g for 10 min at 4°C. Supernatants were then harvested for Western blotting.
Human tissue sample preparation
Human spinal cord tissues were obtained from Johns Hopkins Medical Institute and Department of Veterans Affairs Biorepository Brain Bank (Supplemental Table S2). Tissues were weighed and homogenized with 10 times the sample's volume of modified RIPA buffer (50 mM Tris at pH 7.5, 150 mM NaCl, 1% NP40, 0.1% SDS, 100 mM NaF, 17.5 mM β-glycerophosphate, 2.5% sodium deoxycholate, 10% glycerol) containing phosphatase inhibitors 2 and 3 (1:100; Millipore Sigma), 1 mM PMSF, 2 mM NaVO4, and protease inhibitor (1:200; Millipore Sigma). Samples were then sonicated and diluted with the modified RIPA buffer. After centrifugation at 12,000g for 10 min at 4°C, supernatants were collected for Western blotting.
Differentiation of iPSCs to motor neurons
The iPSCs were obtained from the National Institutes of Health-sponsored repository (Supplemental Table S2). The method for differentiating human iPSCs into motor neurons was adapted from a previous report (Du et al. 2015). The iPSCs were plated on Matrigel-coated plates prior to differentiation. Neuroepithelial progenitor (NEP) cells were generated from iPSCs using neural medum (1:1 DMEM/F12:neurobasal medium, glutamax, N2 supplement, B27 supplement, ascorbic acid), supplemented with 3 µM CHIR99021, 2 µM SB431542, and 2 µM DMH-1 for 6 d, changing medium every other day. NEP cells were then disassociated using 1 U/mL dispase and split approximately 1:6 onto new Matrigel-coated plates. Neural medium supplemented with 1 µM CHIR99021, 2 µM SB431542, 2 µM DMH-1, 0.1 µM retinoic acid (RA), and 0.5 µM purmorphamine was used to generate motor neuron progenitor (MNP) cells from NEPs. The medium was changed every other day for 6 d. To generate motor neuron-like cells, MNPs were disassociated with 1 U/mL dispase and placed in suspension culture using neural medium supplemented with 0.5 µM RA and 0.1 µM purmorphamine, changing medium every other day. After 6 d, motor neuron-like cells were disassociated and plated onto Matrigel-coated plates. Mature motor neurons were generated in 12 d using neural medium supplemented with 0.5 µM RA, 0.1 µM purmorphamine, and 0.1 µM compound E, changing medium every other day.
Statistical analysis
All experiments were independently repeated at least three times. For single comparison, data were statistically analyzed with Student's t-test. For multiple means of comparison, one-way analysis of variance (ANOVA) was performed followed by the Bonferroni post-hoc test to determine statistical significance. The sample size n represents biological replicates. For enrichment analysis, Fisher's test was performed.
Authors: Yoshitsugu Aoki; Raquel Manzano; Yi Lee; Ruxandra Dafinca; Misako Aoki; Andrew G L Douglas; Miguel A Varela; Chaitra Sathyaprakash; Jakub Scaber; Paola Barbagallo; Pieter Vader; Imre Mäger; Kariem Ezzat; Martin R Turner; Naoki Ito; Samanta Gasco; Norihiko Ohbayashi; Samir El Andaloussi; Shin'ichi Takeda; Mitsunori Fukuda; Kevin Talbot; Matthew J A Wood Journal: Brain Date: 2017-04-01 Impact factor: 13.501
Authors: J G O'Rourke; L Bogdanik; A Yáñez; D Lall; A J Wolf; A K M G Muhammad; R Ho; S Carmona; J P Vit; J Zarrow; K J Kim; S Bell; M B Harms; T M Miller; C A Dangler; D M Underhill; H S Goodridge; C M Lutz; R H Baloh Journal: Science Date: 2016-03-18 Impact factor: 47.728
Authors: L Dupuis; P Corcia; A Fergani; J-L Gonzalez De Aguilar; D Bonnefont-Rousselot; R Bittar; D Seilhean; J-J Hauw; L Lacomblez; J-P Loeffler; V Meininger Journal: Neurology Date: 2008-01-16 Impact factor: 9.910
Authors: Christopher J Donnelly; Ping-Wu Zhang; Jacqueline T Pham; Aaron R Haeusler; Aaron R Heusler; Nipun A Mistry; Svetlana Vidensky; Elizabeth L Daley; Erin M Poth; Benjamin Hoover; Daniel M Fines; Nicholas Maragakis; Pentti J Tienari; Leonard Petrucelli; Bryan J Traynor; Jiou Wang; Frank Rigo; C Frank Bennett; Seth Blackshaw; Rita Sattler; Jeffrey D Rothstein Journal: Neuron Date: 2013-10-16 Impact factor: 17.173
Authors: C Bouteloup; J-C Desport; P Clavelou; N Guy; H Derumeaux-Burel; A Ferrier; P Couratier Journal: J Neurol Date: 2009-03-22 Impact factor: 4.849
Authors: Christopher P Cali; Maribel Patino; Yee Kit Tai; Wan Yun Ho; Catriona A McLean; Christopher M Morris; William W Seeley; Bruce L Miller; Carles Gaig; Jean Paul G Vonsattel; Charles L White; Sigrun Roeber; Hans Kretzschmar; Juan C Troncoso; Claire Troakes; Marla Gearing; Bernardino Ghetti; Vivianna M Van Deerlin; Virginia M-Y Lee; John Q Trojanowski; Kin Y Mok; Helen Ling; Dennis W Dickson; Gerard D Schellenberg; Shuo-Chien Ling; Edward B Lee Journal: Acta Neuropathol Date: 2019-07-20 Impact factor: 17.088
Authors: Honghe Liu; Yu-Ning Lu; Tapas Paul; Goran Periz; Michael T Banco; Adrian R Ferré-D'Amaré; Jeffrey D Rothstein; Lindsey R Hayes; Sua Myong; Jiou Wang Journal: J Am Chem Soc Date: 2021-04-15 Impact factor: 15.419
Authors: Daniel J Klionsky; Amal Kamal Abdel-Aziz; Sara Abdelfatah; Mahmoud Abdellatif; Asghar Abdoli; Steffen Abel; Hagai Abeliovich; Marie H Abildgaard; Yakubu Princely Abudu; Abraham Acevedo-Arozena; Iannis E Adamopoulos; Khosrow Adeli; Timon E Adolph; Annagrazia Adornetto; Elma Aflaki; Galila Agam; Anupam Agarwal; Bharat B Aggarwal; Maria Agnello; Patrizia Agostinis; Javed N Agrewala; Alexander Agrotis; Patricia V Aguilar; S Tariq Ahmad; Zubair M Ahmed; Ulises Ahumada-Castro; Sonja Aits; Shu Aizawa; Yunus Akkoc; Tonia Akoumianaki; Hafize Aysin Akpinar; Ahmed M Al-Abd; Lina Al-Akra; Abeer Al-Gharaibeh; Moulay A Alaoui-Jamali; Simon Alberti; Elísabet Alcocer-Gómez; Cristiano Alessandri; Muhammad Ali; M Abdul Alim Al-Bari; Saeb Aliwaini; Javad Alizadeh; Eugènia Almacellas; Alexandru Almasan; Alicia Alonso; Guillermo D Alonso; Nihal Altan-Bonnet; Dario C Altieri; Élida M C Álvarez; Sara Alves; Cristine Alves da Costa; Mazen M Alzaharna; Marialaura Amadio; Consuelo Amantini; Cristina Amaral; Susanna Ambrosio; Amal O Amer; Veena Ammanathan; Zhenyi An; Stig U Andersen; Shaida A Andrabi; Magaiver Andrade-Silva; Allen M Andres; Sabrina Angelini; David Ann; Uche C Anozie; Mohammad Y Ansari; Pedro Antas; Adam Antebi; Zuriñe Antón; Tahira Anwar; Lionel Apetoh; Nadezda Apostolova; Toshiyuki Araki; Yasuhiro Araki; Kohei Arasaki; Wagner L Araújo; Jun Araya; Catherine Arden; Maria-Angeles Arévalo; Sandro Arguelles; Esperanza Arias; Jyothi Arikkath; Hirokazu Arimoto; Aileen R Ariosa; Darius Armstrong-James; Laetitia Arnauné-Pelloquin; Angeles Aroca; Daniela S Arroyo; Ivica Arsov; Rubén Artero; Dalia Maria Lucia Asaro; Michael Aschner; Milad Ashrafizadeh; Osnat Ashur-Fabian; Atanas G Atanasov; Alicia K Au; Patrick Auberger; Holger W Auner; Laure Aurelian; Riccardo Autelli; Laura Avagliano; Yenniffer Ávalos; Sanja Aveic; Célia Alexandra Aveleira; Tamar Avin-Wittenberg; Yucel Aydin; Scott Ayton; Srinivas Ayyadevara; Maria Azzopardi; Misuzu Baba; Jonathan M Backer; Steven K Backues; Dong-Hun Bae; Ok-Nam Bae; Soo Han Bae; Eric H Baehrecke; Ahruem Baek; Seung-Hoon Baek; Sung Hee Baek; Giacinto Bagetta; Agnieszka Bagniewska-Zadworna; Hua Bai; Jie Bai; Xiyuan Bai; Yidong Bai; Nandadulal Bairagi; Shounak Baksi; Teresa Balbi; Cosima T Baldari; Walter Balduini; Andrea Ballabio; Maria Ballester; Salma Balazadeh; Rena Balzan; Rina Bandopadhyay; Sreeparna Banerjee; Sulagna Banerjee; Ágnes Bánréti; Yan Bao; Mauricio S Baptista; Alessandra Baracca; Cristiana Barbati; Ariadna Bargiela; Daniela Barilà; Peter G Barlow; Sami J Barmada; Esther Barreiro; George E Barreto; Jiri Bartek; Bonnie Bartel; Alberto Bartolome; Gaurav R Barve; Suresh H Basagoudanavar; Diane C Bassham; Robert C Bast; Alakananda Basu; Henri Batoko; Isabella Batten; Etienne E Baulieu; Bradley L Baumgarner; Jagadeesh Bayry; Rupert Beale; Isabelle Beau; Florian Beaumatin; Luiz R G Bechara; George R Beck; Michael F Beers; Jakob Begun; Christian Behrends; Georg M N Behrens; Roberto Bei; Eloy Bejarano; Shai Bel; Christian Behl; Amine Belaid; Naïma Belgareh-Touzé; Cristina Bellarosa; Francesca Belleudi; Melissa Belló Pérez; Raquel Bello-Morales; Jackeline Soares de Oliveira Beltran; Sebastián Beltran; Doris Mangiaracina Benbrook; Mykolas Bendorius; Bruno A Benitez; Irene Benito-Cuesta; Julien Bensalem; Martin W Berchtold; Sabina Berezowska; Daniele Bergamaschi; Matteo Bergami; Andreas Bergmann; Laura Berliocchi; Clarisse Berlioz-Torrent; Amélie Bernard; Lionel Berthoux; Cagri G Besirli; Sebastien Besteiro; Virginie M Betin; Rudi Beyaert; Jelena S Bezbradica; Kiran Bhaskar; Ingrid Bhatia-Kissova; Resham Bhattacharya; Sujoy Bhattacharya; Shalmoli Bhattacharyya; Md Shenuarin Bhuiyan; Sujit Kumar Bhutia; Lanrong Bi; Xiaolin Bi; Trevor J Biden; Krikor Bijian; Viktor A Billes; Nadine Binart; Claudia Bincoletto; Asa B Birgisdottir; Geir Bjorkoy; Gonzalo Blanco; Ana Blas-Garcia; Janusz Blasiak; Robert Blomgran; Klas Blomgren; Janice S Blum; Emilio Boada-Romero; Mirta Boban; Kathleen Boesze-Battaglia; Philippe Boeuf; Barry Boland; Pascale Bomont; Paolo Bonaldo; Srinivasa Reddy Bonam; Laura Bonfili; Juan S Bonifacino; Brian A Boone; Martin D Bootman; Matteo Bordi; Christoph Borner; Beat C Bornhauser; Gautam Borthakur; Jürgen Bosch; Santanu Bose; Luis M Botana; Juan Botas; Chantal M Boulanger; Michael E Boulton; Mathieu Bourdenx; Benjamin Bourgeois; Nollaig M Bourke; Guilhem Bousquet; Patricia Boya; Peter V Bozhkov; Luiz H M Bozi; Tolga O Bozkurt; Doug E Brackney; Christian H Brandts; Ralf J Braun; Gerhard H Braus; Roberto Bravo-Sagua; José M Bravo-San Pedro; Patrick Brest; Marie-Agnès Bringer; Alfredo Briones-Herrera; V Courtney Broaddus; Peter Brodersen; Jeffrey L Brodsky; Steven L Brody; Paola G Bronson; Jeff M Bronstein; Carolyn N Brown; Rhoderick E Brown; Patricia C Brum; John H Brumell; Nicola Brunetti-Pierri; Daniele Bruno; Robert J Bryson-Richardson; Cecilia Bucci; Carmen Buchrieser; Marta Bueno; Laura Elisa Buitrago-Molina; Simone Buraschi; Shilpa Buch; J Ross Buchan; Erin M Buckingham; Hikmet Budak; Mauricio Budini; Geert Bultynck; Florin Burada; Joseph R Burgoyne; M Isabel Burón; Victor Bustos; Sabrina Büttner; Elena Butturini; Aaron Byrd; Isabel Cabas; Sandra Cabrera-Benitez; Ken Cadwell; Jingjing Cai; Lu Cai; Qian Cai; Montserrat Cairó; Jose A Calbet; Guy A Caldwell; Kim A Caldwell; Jarrod A Call; Riccardo Calvani; Ana C Calvo; Miguel Calvo-Rubio Barrera; Niels Os Camara; Jacques H Camonis; Nadine Camougrand; Michelangelo Campanella; Edward M Campbell; François-Xavier Campbell-Valois; Silvia Campello; Ilaria Campesi; Juliane C Campos; Olivier Camuzard; Jorge Cancino; Danilo Candido de Almeida; Laura Canesi; Isabella Caniggia; Barbara Canonico; Carles Cantí; Bin Cao; Michele Caraglia; Beatriz Caramés; Evie H Carchman; Elena Cardenal-Muñoz; Cesar Cardenas; Luis Cardenas; Sandra M Cardoso; Jennifer S Carew; Georges F Carle; Gillian Carleton; Silvia Carloni; Didac Carmona-Gutierrez; Leticia A Carneiro; Oliana Carnevali; Julian M Carosi; Serena Carra; Alice Carrier; Lucie Carrier; Bernadette Carroll; A Brent Carter; Andreia Neves Carvalho; Magali Casanova; Caty Casas; Josefina Casas; Chiara Cassioli; Eliseo F Castillo; Karen Castillo; Sonia Castillo-Lluva; Francesca Castoldi; Marco Castori; Ariel F Castro; Margarida Castro-Caldas; Javier Castro-Hernandez; Susana Castro-Obregon; Sergio D Catz; Claudia Cavadas; Federica Cavaliere; Gabriella Cavallini; Maria Cavinato; Maria L Cayuela; Paula Cebollada Rica; Valentina Cecarini; Francesco Cecconi; Marzanna Cechowska-Pasko; Simone Cenci; Victòria Ceperuelo-Mallafré; João J Cerqueira; Janete M Cerutti; Davide Cervia; Vildan Bozok Cetintas; Silvia Cetrullo; Han-Jung Chae; Andrei S Chagin; Chee-Yin Chai; Gopal Chakrabarti; Oishee Chakrabarti; Tapas Chakraborty; Trinad Chakraborty; Mounia Chami; Georgios Chamilos; David W Chan; Edmond Y W Chan; Edward D Chan; H Y Edwin Chan; Helen H Chan; Hung Chan; Matthew T V Chan; Yau Sang Chan; Partha K Chandra; Chih-Peng Chang; Chunmei Chang; Hao-Chun Chang; Kai Chang; Jie Chao; Tracey Chapman; Nicolas Charlet-Berguerand; Samrat Chatterjee; Shail K Chaube; Anu Chaudhary; Santosh Chauhan; Edward Chaum; Frédéric Checler; Michael E Cheetham; Chang-Shi Chen; Guang-Chao Chen; Jian-Fu Chen; Liam L Chen; Leilei Chen; Lin Chen; Mingliang Chen; Mu-Kuan Chen; Ning Chen; Quan Chen; Ruey-Hwa Chen; Shi Chen; Wei Chen; Weiqiang Chen; Xin-Ming Chen; Xiong-Wen Chen; Xu Chen; Yan Chen; Ye-Guang Chen; Yingyu Chen; Yongqiang Chen; Yu-Jen Chen; Yue-Qin Chen; Zhefan Stephen Chen; Zhi Chen; Zhi-Hua Chen; Zhijian J Chen; Zhixiang Chen; Hanhua Cheng; Jun Cheng; Shi-Yuan Cheng; Wei Cheng; Xiaodong Cheng; Xiu-Tang Cheng; Yiyun Cheng; Zhiyong Cheng; Zhong Chen; Heesun Cheong; Jit Kong Cheong; Boris V Chernyak; Sara Cherry; Chi Fai Randy Cheung; Chun Hei Antonio Cheung; King-Ho Cheung; Eric Chevet; Richard J Chi; Alan Kwok Shing Chiang; Ferdinando Chiaradonna; Roberto Chiarelli; Mario Chiariello; Nathalia Chica; Susanna Chiocca; Mario Chiong; Shih-Hwa Chiou; Abhilash I Chiramel; Valerio Chiurchiù; Dong-Hyung Cho; Seong-Kyu Choe; Augustine M K Choi; Mary E Choi; Kamalika Roy Choudhury; Norman S Chow; Charleen T Chu; Jason P Chua; John Jia En Chua; Hyewon Chung; Kin Pan Chung; Seockhoon Chung; So-Hyang Chung; Yuen-Li Chung; Valentina Cianfanelli; Iwona A Ciechomska; Mariana Cifuentes; Laura Cinque; Sebahattin Cirak; Mara Cirone; Michael J Clague; Robert Clarke; Emilio Clementi; Eliana M Coccia; Patrice Codogno; Ehud Cohen; Mickael M Cohen; Tania Colasanti; Fiorella Colasuonno; Robert A Colbert; Anna Colell; Miodrag Čolić; Nuria S Coll; Mark O Collins; María I Colombo; Daniel A Colón-Ramos; Lydie Combaret; Sergio Comincini; Márcia R Cominetti; Antonella Consiglio; Andrea Conte; Fabrizio Conti; Viorica Raluca Contu; Mark R Cookson; Kevin M Coombs; Isabelle Coppens; Maria Tiziana Corasaniti; Dale P Corkery; Nils Cordes; Katia Cortese; Maria do Carmo Costa; Sarah Costantino; Paola Costelli; Ana Coto-Montes; Peter J Crack; Jose L Crespo; Alfredo Criollo; Valeria Crippa; Riccardo Cristofani; Tamas Csizmadia; Antonio Cuadrado; Bing Cui; Jun Cui; Yixian Cui; Yong Cui; Emmanuel Culetto; Andrea C Cumino; Andrey V Cybulsky; Mark J Czaja; Stanislaw J Czuczwar; Stefania D'Adamo; Marcello D'Amelio; Daniela D'Arcangelo; Andrew C D'Lugos; Gabriella D'Orazi; James A da Silva; Hormos Salimi Dafsari; Ruben K Dagda; Yasin Dagdas; Maria Daglia; Xiaoxia Dai; Yun Dai; Yuyuan Dai; Jessica Dal Col; Paul Dalhaimer; Luisa Dalla Valle; Tobias Dallenga; Guillaume Dalmasso; Markus Damme; Ilaria Dando; Nico P Dantuma; April L Darling; Hiranmoy Das; Srinivasan Dasarathy; Santosh K Dasari; Srikanta Dash; Oliver Daumke; Adrian N Dauphinee; Jeffrey S Davies; Valeria A Dávila; Roger J Davis; Tanja Davis; Sharadha Dayalan Naidu; Francesca De Amicis; Karolien De Bosscher; Francesca De Felice; Lucia De Franceschi; Chiara De Leonibus; Mayara G de Mattos Barbosa; Guido R Y De Meyer; Angelo De Milito; Cosimo De Nunzio; Clara De Palma; Mauro De Santi; Claudio De Virgilio; Daniela De Zio; Jayanta Debnath; Brian J DeBosch; Jean-Paul Decuypere; Mark A Deehan; Gianluca Deflorian; James DeGregori; Benjamin Dehay; Gabriel Del Rio; Joe R Delaney; Lea M D Delbridge; Elizabeth Delorme-Axford; M Victoria Delpino; Francesca Demarchi; Vilma Dembitz; Nicholas D Demers; Hongbin Deng; Zhiqiang Deng; Joern Dengjel; Paul Dent; Donna Denton; Melvin L DePamphilis; Channing J Der; Vojo Deretic; Albert Descoteaux; Laura Devis; Sushil Devkota; Olivier Devuyst; Grant Dewson; Mahendiran Dharmasivam; Rohan Dhiman; Diego di Bernardo; Manlio Di Cristina; Fabio Di Domenico; Pietro Di Fazio; Alessio Di Fonzo; Giovanni Di Guardo; Gianni M Di Guglielmo; Luca Di Leo; Chiara Di Malta; Alessia Di Nardo; Martina Di Rienzo; Federica Di Sano; George Diallinas; Jiajie Diao; Guillermo Diaz-Araya; Inés Díaz-Laviada; Jared M Dickinson; Marc Diederich; Mélanie Dieudé; Ivan Dikic; Shiping Ding; Wen-Xing Ding; Luciana Dini; Jelena Dinić; Miroslav Dinic; Albena T Dinkova-Kostova; Marc S Dionne; Jörg H W Distler; Abhinav Diwan; Ian M C Dixon; Mojgan Djavaheri-Mergny; Ina Dobrinski; Oxana Dobrovinskaya; Radek Dobrowolski; Renwick C J Dobson; Jelena Đokić; Serap Dokmeci Emre; Massimo Donadelli; Bo Dong; Xiaonan Dong; Zhiwu Dong; Gerald W Dorn Ii; Volker Dotsch; Huan Dou; Juan Dou; Moataz Dowaidar; Sami Dridi; Liat Drucker; Ailian Du; Caigan Du; Guangwei Du; Hai-Ning Du; Li-Lin Du; André du Toit; Shao-Bin Duan; Xiaoqiong Duan; Sónia P Duarte; Anna Dubrovska; Elaine A Dunlop; Nicolas Dupont; Raúl V Durán; Bilikere S Dwarakanath; Sergey A Dyshlovoy; Darius Ebrahimi-Fakhari; Leopold Eckhart; Charles L Edelstein; Thomas Efferth; Eftekhar Eftekharpour; Ludwig Eichinger; Nabil Eid; Tobias Eisenberg; N Tony Eissa; Sanaa Eissa; Miriam Ejarque; Abdeljabar El Andaloussi; Nazira El-Hage; Shahenda El-Naggar; Anna Maria Eleuteri; Eman S El-Shafey; Mohamed Elgendy; Aristides G Eliopoulos; María M Elizalde; Philip M Elks; Hans-Peter Elsasser; Eslam S Elsherbiny; Brooke M Emerling; N C Tolga Emre; Christina H Eng; Nikolai Engedal; Anna-Mart Engelbrecht; Agnete S T Engelsen; Jorrit M Enserink; Ricardo Escalante; Audrey Esclatine; Mafalda Escobar-Henriques; Eeva-Liisa Eskelinen; Lucile Espert; Makandjou-Ola Eusebio; Gemma Fabrias; Cinzia Fabrizi; Antonio Facchiano; Francesco Facchiano; Bengt Fadeel; Claudio Fader; Alex C Faesen; W Douglas Fairlie; Alberto Falcó; Bjorn H Falkenburger; Daping Fan; Jie Fan; Yanbo Fan; Evandro F Fang; Yanshan Fang; Yognqi Fang; Manolis Fanto; Tamar Farfel-Becker; Mathias Faure; Gholamreza Fazeli; Anthony O Fedele; Arthur M Feldman; Du Feng; Jiachun Feng; Lifeng Feng; Yibin Feng; Yuchen Feng; Wei Feng; Thais Fenz Araujo; Thomas A Ferguson; Álvaro F Fernández; Jose C Fernandez-Checa; Sonia Fernández-Veledo; Alisdair R Fernie; Anthony W Ferrante; Alessandra Ferraresi; Merari F Ferrari; Julio C B Ferreira; Susan Ferro-Novick; Antonio Figueras; Riccardo Filadi; Nicoletta Filigheddu; Eduardo Filippi-Chiela; Giuseppe Filomeni; Gian Maria Fimia; Vittorio Fineschi; Francesca Finetti; Steven Finkbeiner; Edward A Fisher; Paul B Fisher; Flavio Flamigni; Steven J Fliesler; Trude H Flo; Ida Florance; Oliver Florey; Tullio Florio; Erika Fodor; Carlo Follo; Edward A Fon; Antonella Forlino; Francesco Fornai; Paola Fortini; Anna Fracassi; Alessandro Fraldi; Brunella Franco; Rodrigo Franco; Flavia Franconi; Lisa B Frankel; Scott L Friedman; Leopold F Fröhlich; Gema Frühbeck; Jose M Fuentes; Yukio Fujiki; Naonobu Fujita; Yuuki Fujiwara; Mitsunori Fukuda; Simone Fulda; Luc Furic; Norihiko Furuya; Carmela Fusco; Michaela U Gack; Lidia Gaffke; Sehamuddin Galadari; Alessia Galasso; Maria F Galindo; Sachith Gallolu Kankanamalage; Lorenzo Galluzzi; Vincent Galy; Noor Gammoh; Boyi Gan; Ian G Ganley; Feng Gao; Hui Gao; Minghui Gao; Ping Gao; Shou-Jiang Gao; Wentao Gao; Xiaobo Gao; Ana Garcera; Maria Noé Garcia; Verónica E Garcia; Francisco García-Del Portillo; Vega Garcia-Escudero; Aracely Garcia-Garcia; Marina Garcia-Macia; Diana García-Moreno; Carmen Garcia-Ruiz; Patricia García-Sanz; Abhishek D Garg; Ricardo Gargini; Tina Garofalo; Robert F Garry; Nils C Gassen; Damian Gatica; Liang Ge; Wanzhong Ge; Ruth Geiss-Friedlander; Cecilia Gelfi; Pascal Genschik; Ian E Gentle; Valeria Gerbino; Christoph Gerhardt; Kyla Germain; Marc Germain; David A Gewirtz; Elham Ghasemipour Afshar; Saeid Ghavami; Alessandra Ghigo; Manosij Ghosh; Georgios Giamas; Claudia Giampietri; Alexandra Giatromanolaki; Gary E Gibson; Spencer B Gibson; Vanessa Ginet; Edward Giniger; Carlotta Giorgi; Henrique Girao; Stephen E Girardin; Mridhula Giridharan; Sandy Giuliano; Cecilia Giulivi; Sylvie Giuriato; Julien Giustiniani; Alexander Gluschko; Veit Goder; Alexander Goginashvili; Jakub Golab; David C Goldstone; Anna Golebiewska; Luciana R Gomes; Rodrigo Gomez; Rubén Gómez-Sánchez; Maria Catalina Gomez-Puerto; Raquel Gomez-Sintes; Qingqiu Gong; Felix M Goni; Javier González-Gallego; Tomas Gonzalez-Hernandez; Rosa A Gonzalez-Polo; Jose A Gonzalez-Reyes; Patricia González-Rodríguez; Ing Swie Goping; Marina S Gorbatyuk; Nikolai V Gorbunov; Kıvanç Görgülü; Roxana M Gorojod; Sharon M Gorski; Sandro Goruppi; Cecilia Gotor; Roberta A Gottlieb; Illana Gozes; Devrim Gozuacik; Martin Graef; Markus H Gräler; Veronica Granatiero; Daniel Grasso; Joshua P Gray; Douglas R Green; Alexander Greenhough; Stephen L Gregory; Edward F Griffin; Mark W Grinstaff; Frederic Gros; Charles Grose; Angelina S Gross; Florian Gruber; Paolo Grumati; Tilman Grune; Xueyan Gu; Jun-Lin Guan; Carlos M Guardia; Kishore Guda; Flora Guerra; Consuelo Guerri; Prasun Guha; Carlos Guillén; Shashi Gujar; Anna Gukovskaya; Ilya Gukovsky; Jan Gunst; Andreas Günther; Anyonya R Guntur; Chuanyong Guo; Chun Guo; Hongqing Guo; Lian-Wang Guo; Ming Guo; Pawan Gupta; Shashi Kumar Gupta; Swapnil Gupta; Veer Bala Gupta; Vivek Gupta; Asa B Gustafsson; David D Gutterman; Ranjitha H B; Annakaisa Haapasalo; James E Haber; Aleksandra Hać; Shinji Hadano; Anders J Hafrén; Mansour Haidar; Belinda S Hall; Gunnel Halldén; Anne Hamacher-Brady; Andrea Hamann; Maho Hamasaki; Weidong Han; Malene Hansen; Phyllis I Hanson; Zijian Hao; Masaru Harada; Ljubica Harhaji-Trajkovic; Nirmala Hariharan; Nigil Haroon; James Harris; Takafumi Hasegawa; Noor Hasima Nagoor; Jeffrey A Haspel; Volker Haucke; Wayne D Hawkins; Bruce A Hay; Cole M Haynes; Soren B Hayrabedyan; Thomas S Hays; Congcong He; Qin He; Rong-Rong He; You-Wen He; Yu-Ying He; Yasser Heakal; Alexander M Heberle; J Fielding Hejtmancik; Gudmundur Vignir Helgason; Vanessa Henkel; Marc Herb; Alexander Hergovich; Anna Herman-Antosiewicz; Agustín Hernández; Carlos Hernandez; Sergio Hernandez-Diaz; Virginia Hernandez-Gea; Amaury Herpin; Judit Herreros; Javier H Hervás; Daniel Hesselson; Claudio Hetz; Volker T Heussler; Yujiro Higuchi; Sabine Hilfiker; Joseph A Hill; William S Hlavacek; Emmanuel A Ho; Idy H T Ho; Philip Wing-Lok Ho; Shu-Leong Ho; Wan Yun Ho; G Aaron Hobbs; Mark Hochstrasser; Peter H M Hoet; Daniel Hofius; Paul Hofman; Annika Höhn; Carina I Holmberg; Jose R Hombrebueno; Chang-Won Hong Yi-Ren Hong; Lora V Hooper; Thorsten Hoppe; Rastislav Horos; Yujin Hoshida; I-Lun Hsin; Hsin-Yun Hsu; Bing Hu; Dong Hu; Li-Fang Hu; Ming Chang Hu; Ronggui Hu; Wei Hu; Yu-Chen Hu; Zhuo-Wei Hu; Fang Hua; Jinlian Hua; Yingqi Hua; Chongmin Huan; Canhua Huang; Chuanshu Huang; Chuanxin Huang; Chunling Huang; Haishan Huang; Kun Huang; Michael L H Huang; Rui Huang; Shan Huang; Tianzhi Huang; Xing Huang; Yuxiang Jack Huang; Tobias B Huber; Virginie Hubert; Christian A Hubner; Stephanie M Hughes; William E Hughes; Magali Humbert; Gerhard Hummer; James H Hurley; Sabah Hussain; Salik Hussain; Patrick J Hussey; Martina Hutabarat; Hui-Yun Hwang; Seungmin Hwang; Antonio Ieni; Fumiyo Ikeda; Yusuke Imagawa; Yuzuru Imai; Carol Imbriano; Masaya Imoto; Denise M Inman; Ken Inoki; Juan Iovanna; Renato V Iozzo; Giuseppe Ippolito; Javier E Irazoqui; Pablo Iribarren; Mohd Ishaq; Makoto Ishikawa; Nestor Ishimwe; Ciro Isidoro; Nahed Ismail; Shohreh Issazadeh-Navikas; Eisuke Itakura; Daisuke Ito; Davor Ivankovic; Saška Ivanova; Anand Krishnan V Iyer; José M Izquierdo; Masanori Izumi; Marja Jäättelä; Majid Sakhi Jabir; William T Jackson; Nadia Jacobo-Herrera; Anne-Claire Jacomin; Elise Jacquin; Pooja Jadiya; Hartmut Jaeschke; Chinnaswamy Jagannath; Arjen J Jakobi; Johan Jakobsson; Bassam Janji; Pidder Jansen-Dürr; Patric J Jansson; Jonathan Jantsch; Sławomir Januszewski; Alagie Jassey; Steve Jean; Hélène Jeltsch-David; Pavla Jendelova; Andreas Jenny; Thomas E Jensen; Niels Jessen; Jenna L Jewell; Jing Ji; Lijun Jia; Rui Jia; Liwen Jiang; Qing Jiang; Richeng Jiang; Teng Jiang; Xuejun Jiang; Yu Jiang; Maria Jimenez-Sanchez; Eun-Jung Jin; Fengyan Jin; Hongchuan Jin; Li Jin; Luqi Jin; Meiyan Jin; Si Jin; Eun-Kyeong Jo; Carine Joffre; Terje Johansen; Gail V W Johnson; Simon A Johnston; Eija Jokitalo; Mohit Kumar Jolly; Leo A B Joosten; Joaquin Jordan; Bertrand Joseph; Dianwen Ju; Jeong-Sun Ju; Jingfang Ju; Esmeralda Juárez; Delphine Judith; Gábor Juhász; Youngsoo Jun; Chang Hwa Jung; Sung-Chul Jung; Yong Keun Jung; Heinz Jungbluth; Johannes Jungverdorben; Steffen Just; Kai Kaarniranta; Allen Kaasik; Tomohiro Kabuta; Daniel Kaganovich; Alon Kahana; Renate Kain; Shinjo Kajimura; Maria Kalamvoki; Manjula Kalia; Danuta S Kalinowski; Nina Kaludercic; Ioanna Kalvari; Joanna Kaminska; Vitaliy O Kaminskyy; Hiromitsu Kanamori; Keizo Kanasaki; Chanhee Kang; Rui Kang; Sang Sun Kang; Senthilvelrajan Kaniyappan; Tomotake Kanki; Thirumala-Devi Kanneganti; Anumantha G Kanthasamy; Arthi Kanthasamy; Marc Kantorow; Orsolya Kapuy; Michalis V Karamouzis; Md Razaul Karim; Parimal Karmakar; Rajesh G Katare; Masaru Kato; Stefan H E Kaufmann; Anu Kauppinen; Gur P Kaushal; Susmita Kaushik; Kiyoshi Kawasaki; Kemal Kazan; Po-Yuan Ke; Damien J Keating; Ursula Keber; John H Kehrl; Kate E Keller; Christian W Keller; Jongsook Kim Kemper; Candia M Kenific; Oliver Kepp; Stephanie Kermorgant; Andreas Kern; Robin Ketteler; Tom G Keulers; Boris Khalfin; Hany Khalil; Bilon Khambu; Shahid Y Khan; Vinoth Kumar Megraj Khandelwal; Rekha Khandia; Widuri Kho; Noopur V Khobrekar; Sataree Khuansuwan; Mukhran Khundadze; Samuel A Killackey; Dasol Kim; Deok Ryong Kim; Do-Hyung Kim; Dong-Eun Kim; Eun Young Kim; Eun-Kyoung Kim; Hak-Rim Kim; Hee-Sik Kim; Jeong Hun Kim; Jin Kyung Kim; Jin-Hoi Kim; Joungmok Kim; Ju Hwan Kim; Keun Il Kim; Peter K Kim; Seong-Jun Kim; Scot R Kimball; Adi Kimchi; Alec C Kimmelman; Tomonori Kimura; Matthew A King; Kerri J Kinghorn; Conan G Kinsey; Vladimir Kirkin; Lorrie A Kirshenbaum; Sergey L Kiselev; Shuji Kishi; Katsuhiko Kitamoto; Yasushi Kitaoka; Kaio Kitazato; Richard N Kitsis; Josef T Kittler; Ole Kjaerulff; Peter S Klein; Thomas Klopstock; Jochen Klucken; Helene Knævelsrud; Roland L Knorr; Ben C B Ko; Fred Ko; Jiunn-Liang Ko; Hotaka Kobayashi; Satoru Kobayashi; Ina Koch; Jan C Koch; Ulrich Koenig; Donat Kögel; Young Ho Koh; Masato Koike; Sepp D Kohlwein; Nur M Kocaturk; Masaaki Komatsu; Jeannette König; Toru Kono; Benjamin T Kopp; Tamas Korcsmaros; Gözde Korkmaz; Viktor I Korolchuk; Mónica Suárez Korsnes; Ali Koskela; Janaiah Kota; Yaichiro Kotake; Monica L Kotler; Yanjun Kou; Michael I Koukourakis; Evangelos Koustas; Attila L Kovacs; Tibor Kovács; Daisuke Koya; Tomohiro Kozako; Claudine Kraft; Dimitri Krainc; Helmut Krämer; Anna D Krasnodembskaya; Carole Kretz-Remy; Guido Kroemer; Nicholas T Ktistakis; Kazuyuki Kuchitsu; Sabine Kuenen; Lars Kuerschner; Thomas Kukar; Ajay Kumar; Ashok Kumar; Deepak Kumar; Dhiraj Kumar; Sharad Kumar; Shinji Kume; Caroline Kumsta; Chanakya N Kundu; Mondira Kundu; Ajaikumar B Kunnumakkara; Lukasz Kurgan; Tatiana G Kutateladze; Ozlem Kutlu; SeongAe Kwak; Ho Jeong Kwon; Taeg Kyu Kwon; Yong Tae Kwon; Irene Kyrmizi; Albert La Spada; Patrick Labonté; Sylvain Ladoire; Ilaria Laface; Frank Lafont; Diane C Lagace; Vikramjit Lahiri; Zhibing Lai; Angela S Laird; Aparna Lakkaraju; Trond Lamark; Sheng-Hui Lan; Ane Landajuela; Darius J R Lane; Jon D Lane; Charles H Lang; Carsten Lange; Ülo Langel; Rupert Langer; Pierre Lapaquette; Jocelyn Laporte; Nicholas F LaRusso; Isabel Lastres-Becker; Wilson Chun Yu Lau; Gordon W Laurie; Sergio Lavandero; Betty Yuen Kwan Law; Helen Ka-Wai Law; Rob Layfield; Weidong Le; Herve Le Stunff; Alexandre Y Leary; Jean-Jacques Lebrun; Lionel Y W Leck; Jean-Philippe Leduc-Gaudet; Changwook Lee; Chung-Pei Lee; Da-Hye Lee; Edward B Lee; Erinna F Lee; Gyun Min Lee; He-Jin Lee; Heung Kyu Lee; Jae Man Lee; Jason S Lee; Jin-A Lee; Joo-Yong Lee; Jun Hee Lee; Michael Lee; Min Goo Lee; Min Jae Lee; Myung-Shik Lee; Sang Yoon Lee; Seung-Jae Lee; Stella Y Lee; Sung Bae Lee; Won Hee Lee; Ying-Ray Lee; Yong-Ho Lee; Youngil Lee; Christophe Lefebvre; Renaud Legouis; Yu L Lei; Yuchen Lei; Sergey Leikin; Gerd Leitinger; Leticia Lemus; Shuilong Leng; Olivia Lenoir; Guido Lenz; Heinz Josef Lenz; Paola Lenzi; Yolanda León; Andréia M Leopoldino; Christoph Leschczyk; Stina Leskelä; Elisabeth Letellier; Chi-Ting Leung; Po Sing Leung; Jeremy S Leventhal; Beth Levine; Patrick A Lewis; Klaus Ley; Bin Li; Da-Qiang Li; Jianming Li; Jing Li; Jiong Li; Ke Li; Liwu Li; Mei Li; Min Li; Min Li; Ming Li; Mingchuan Li; Pin-Lan Li; Ming-Qing Li; Qing Li; Sheng Li; Tiangang Li; Wei Li; Wenming Li; Xue Li; Yi-Ping Li; Yuan Li; Zhiqiang Li; Zhiyong Li; Zhiyuan Li; Jiqin Lian; Chengyu Liang; Qiangrong Liang; Weicheng Liang; Yongheng Liang; YongTian Liang; Guanghong Liao; Lujian Liao; Mingzhi Liao; Yung-Feng Liao; Mariangela Librizzi; Pearl P Y Lie; Mary A Lilly; Hyunjung J Lim; Thania R R Lima; Federica Limana; Chao Lin; Chih-Wen Lin; Dar-Shong Lin; Fu-Cheng Lin; Jiandie D Lin; Kurt M Lin; Kwang-Huei Lin; Liang-Tzung Lin; Pei-Hui Lin; Qiong Lin; Shaofeng Lin; Su-Ju Lin; Wenyu Lin; Xueying Lin; Yao-Xin Lin; Yee-Shin Lin; Rafael Linden; Paula Lindner; Shuo-Chien Ling; Paul Lingor; Amelia K Linnemann; Yih-Cherng Liou; Marta M Lipinski; Saška Lipovšek; Vitor A Lira; Natalia Lisiak; Paloma B Liton; Chao Liu; Ching-Hsuan Liu; Chun-Feng Liu; Cui Hua Liu; Fang Liu; Hao Liu; Hsiao-Sheng Liu; Hua-Feng Liu; Huifang Liu; Jia Liu; Jing Liu; Julia Liu; Leyuan Liu; Longhua Liu; Meilian Liu; Qin Liu; Wei Liu; Wende Liu; Xiao-Hong Liu; Xiaodong Liu; Xingguo Liu; Xu Liu; Xuedong Liu; Yanfen Liu; Yang Liu; Yang Liu; Yueyang Liu; Yule Liu; J Andrew Livingston; Gerard Lizard; Jose M Lizcano; Senka Ljubojevic-Holzer; Matilde E LLeonart; David Llobet-Navàs; Alicia Llorente; Chih Hung Lo; Damián Lobato-Márquez; Qi Long; Yun Chau Long; Ben Loos; Julia A Loos; Manuela G López; Guillermo López-Doménech; José Antonio López-Guerrero; Ana T López-Jiménez; Óscar López-Pérez; Israel López-Valero; Magdalena J Lorenowicz; Mar Lorente; Peter Lorincz; Laura Lossi; Sophie Lotersztajn; Penny E Lovat; Jonathan F Lovell; Alenka Lovy; Péter Lőw; Guang Lu; Haocheng Lu; Jia-Hong Lu; Jin-Jian Lu; Mengji Lu; Shuyan Lu; Alessandro Luciani; John M Lucocq; Paula Ludovico; Micah A Luftig; Morten Luhr; Diego Luis-Ravelo; Julian J Lum; Liany Luna-Dulcey; Anders H Lund; Viktor K Lund; Jan D Lünemann; Patrick Lüningschrör; Honglin Luo; Rongcan Luo; Shouqing Luo; Zhi Luo; Claudio Luparello; Bernhard Lüscher; Luan Luu; Alex Lyakhovich; Konstantin G Lyamzaev; Alf Håkon Lystad; Lyubomyr Lytvynchuk; Alvin C Ma; Changle Ma; Mengxiao Ma; Ning-Fang Ma; Quan-Hong Ma; Xinliang Ma; Yueyun Ma; Zhenyi Ma; Ormond A MacDougald; Fernando Macian; Gustavo C MacIntosh; Jeffrey P MacKeigan; Kay F Macleod; Sandra Maday; Frank Madeo; Muniswamy Madesh; Tobias Madl; Julio Madrigal-Matute; Akiko Maeda; Yasuhiro Maejima; Marta Magarinos; Poornima Mahavadi; Emiliano Maiani; Kenneth Maiese; Panchanan Maiti; Maria Chiara Maiuri; Barbara Majello; Michael B Major; Elena Makareeva; Fayaz Malik; Karthik Mallilankaraman; Walter Malorni; Alina Maloyan; Najiba Mammadova; Gene Chi Wai Man; Federico Manai; Joseph D Mancias; Eva-Maria Mandelkow; Michael A Mandell; Angelo A Manfredi; Masoud H Manjili; Ravi Manjithaya; Patricio Manque; Bella B Manshian; Raquel Manzano; Claudia Manzoni; Kai Mao; Cinzia Marchese; Sandrine Marchetti; Anna Maria Marconi; Fabrizio Marcucci; Stefania Mardente; Olga A Mareninova; Marta Margeta; Muriel Mari; Sara Marinelli; Oliviero Marinelli; Guillermo Mariño; Sofia Mariotto; Richard S Marshall; Mark R Marten; Sascha Martens; Alexandre P J Martin; Katie R Martin; Sara Martin; Shaun Martin; Adrián Martín-Segura; Miguel A Martín-Acebes; Inmaculada Martin-Burriel; Marcos Martin-Rincon; Paloma Martin-Sanz; José A Martina; Wim Martinet; Aitor Martinez; Ana Martinez; Jennifer Martinez; Moises Martinez Velazquez; Nuria Martinez-Lopez; Marta Martinez-Vicente; Daniel O Martins; Joilson O Martins; Waleska K Martins; Tania Martins-Marques; Emanuele Marzetti; Shashank Masaldan; Celine Masclaux-Daubresse; Douglas G Mashek; Valentina Massa; Lourdes Massieu; Glenn R Masson; Laura Masuelli; Anatoliy I Masyuk; Tetyana V Masyuk; Paola Matarrese; Ander Matheu; Satoaki Matoba; Sachiko Matsuzaki; Pamela Mattar; Alessandro Matte; Domenico Mattoscio; José L Mauriz; Mario Mauthe; Caroline Mauvezin; Emanual Maverakis; Paola Maycotte; Johanna Mayer; Gianluigi Mazzoccoli; Cristina Mazzoni; Joseph R Mazzulli; Nami McCarty; Christine McDonald; Mitchell R McGill; Sharon L McKenna; BethAnn McLaughlin; Fionn McLoughlin; Mark A McNiven; Thomas G McWilliams; Fatima Mechta-Grigoriou; Tania Catarina Medeiros; Diego L Medina; Lynn A Megeney; Klara Megyeri; Maryam Mehrpour; Jawahar L Mehta; Alfred J Meijer; Annemarie H Meijer; Jakob Mejlvang; Alicia Meléndez; Annette Melk; Gonen Memisoglu; Alexandrina F Mendes; Delong Meng; Fei Meng; Tian Meng; Rubem Menna-Barreto; Manoj B Menon; Carol Mercer; Anne E Mercier; Jean-Louis Mergny; Adalberto Merighi; Seth D Merkley; Giuseppe Merla; Volker Meske; Ana Cecilia Mestre; Shree Padma Metur; Christian Meyer; Hemmo Meyer; Wenyi Mi; Jeanne Mialet-Perez; Junying Miao; Lucia Micale; Yasuo Miki; Enrico Milan; Małgorzata Milczarek; Dana L Miller; Samuel I Miller; Silke Miller; Steven W Millward; Ira Milosevic; Elena A Minina; Hamed Mirzaei; Hamid Reza Mirzaei; Mehdi Mirzaei; Amit Mishra; Nandita Mishra; Paras Kumar Mishra; Maja Misirkic Marjanovic; Roberta Misasi; Amit Misra; Gabriella Misso; Claire Mitchell; Geraldine Mitou; Tetsuji Miura; Shigeki Miyamoto; Makoto Miyazaki; Mitsunori Miyazaki; Taiga Miyazaki; Keisuke Miyazawa; Noboru Mizushima; Trine H Mogensen; Baharia Mograbi; Reza Mohammadinejad; Yasir Mohamud; Abhishek Mohanty; Sipra Mohapatra; Torsten Möhlmann; Asif Mohmmed; Anna Moles; Kelle H Moley; Maurizio Molinari; Vincenzo Mollace; Andreas Buch Møller; Bertrand Mollereau; Faustino Mollinedo; Costanza Montagna; Mervyn J Monteiro; Andrea Montella; L Ruth Montes; Barbara Montico; Vinod K Mony; Giacomo Monzio Compagnoni; Michael N Moore; Mohammad A Moosavi; Ana L Mora; Marina Mora; David Morales-Alamo; Rosario Moratalla; Paula I Moreira; Elena Morelli; Sandra Moreno; Daniel Moreno-Blas; Viviana Moresi; Benjamin Morga; Alwena H Morgan; Fabrice Morin; Hideaki Morishita; Orson L Moritz; Mariko Moriyama; Yuji Moriyasu; Manuela Morleo; Eugenia Morselli; Jose F Moruno-Manchon; Jorge Moscat; Serge Mostowy; Elisa Motori; Andrea Felinto Moura; Naima Moustaid-Moussa; Maria Mrakovcic; Gabriel Muciño-Hernández; Anupam Mukherjee; Subhadip Mukhopadhyay; Jean M Mulcahy Levy; Victoriano Mulero; Sylviane Muller; Christian Münch; Ashok Munjal; Pura Munoz-Canoves; Teresa Muñoz-Galdeano; Christian Münz; Tomokazu Murakawa; Claudia Muratori; Brona M Murphy; J Patrick Murphy; Aditya Murthy; Timo T Myöhänen; Indira U Mysorekar; Jennifer Mytych; Seyed Mohammad Nabavi; Massimo Nabissi; Péter Nagy; Jihoon Nah; Aimable Nahimana; Ichiro Nakagawa; Ken Nakamura; Hitoshi Nakatogawa; Shyam S Nandi; Meera Nanjundan; Monica Nanni; Gennaro Napolitano; Roberta Nardacci; Masashi Narita; Melissa Nassif; Ilana Nathan; Manabu Natsumeda; Ryno J Naude; Christin Naumann; Olaia Naveiras; Fatemeh Navid; Steffan T Nawrocki; Taras Y Nazarko; Francesca Nazio; Florentina Negoita; Thomas Neill; Amanda L Neisch; Luca M Neri; Mihai G Netea; Patrick Neubert; Thomas P Neufeld; Dietbert Neumann; Albert Neutzner; Phillip T Newton; Paul A Ney; Ioannis P Nezis; Charlene C W Ng; Tzi Bun Ng; Hang T T Nguyen; Long T Nguyen; Hong-Min Ni; Clíona Ní Cheallaigh; Zhenhong Ni; M Celeste Nicolao; Francesco Nicoli; Manuel Nieto-Diaz; Per Nilsson; Shunbin Ning; Rituraj Niranjan; Hiroshi Nishimune; Mireia Niso-Santano; Ralph A Nixon; Annalisa Nobili; Clevio Nobrega; Takeshi Noda; Uxía Nogueira-Recalde; Trevor M Nolan; Ivan Nombela; Ivana Novak; Beatriz Novoa; Takashi Nozawa; Nobuyuki Nukina; Carmen Nussbaum-Krammer; Jesper Nylandsted; Tracey R O'Donovan; Seónadh M O'Leary; Eyleen J O'Rourke; Mary P O'Sullivan; Timothy E O'Sullivan; Salvatore Oddo; Ina Oehme; Michinaga Ogawa; Eric Ogier-Denis; Margret H Ogmundsdottir; Besim Ogretmen; Goo Taeg Oh; Seon-Hee Oh; Young J Oh; Takashi Ohama; Yohei Ohashi; Masaki Ohmuraya; Vasileios Oikonomou; Rani Ojha; Koji Okamoto; Hitoshi Okazawa; Masahide Oku; Sara Oliván; Jorge M A Oliveira; Michael Ollmann; James A Olzmann; Shakib Omari; M Bishr Omary; Gizem Önal; Martin Ondrej; Sang-Bing Ong; Sang-Ging Ong; Anna Onnis; Juan A Orellana; Sara Orellana-Muñoz; Maria Del Mar Ortega-Villaizan; Xilma R Ortiz-Gonzalez; Elena Ortona; Heinz D Osiewacz; Abdel-Hamid K Osman; Rosario Osta; Marisa S Otegui; Kinya Otsu; Christiane Ott; Luisa Ottobrini; Jing-Hsiung James Ou; Tiago F Outeiro; Inger Oynebraten; Melek Ozturk; Gilles Pagès; Susanta Pahari; Marta Pajares; Utpal B Pajvani; Rituraj Pal; Simona Paladino; Nicolas Pallet; Michela Palmieri; Giuseppe Palmisano; Camilla Palumbo; Francesco Pampaloni; Lifeng Pan; Qingjun Pan; Wenliang Pan; Xin Pan; Ganna Panasyuk; Rahul Pandey; Udai B Pandey; Vrajesh Pandya; Francesco Paneni; Shirley Y Pang; Elisa Panzarini; Daniela L Papademetrio; Elena Papaleo; Daniel Papinski; Diana Papp; Eun Chan Park; Hwan Tae Park; Ji-Man Park; Jong-In Park; Joon Tae Park; Junsoo Park; Sang Chul Park; Sang-Youel Park; Abraham H Parola; Jan B Parys; Adrien Pasquier; Benoit Pasquier; João F Passos; Nunzia Pastore; Hemal H Patel; Daniel Patschan; Sophie Pattingre; Gustavo Pedraza-Alva; Jose Pedraza-Chaverri; Zully Pedrozo; Gang Pei; Jianming Pei; Hadas Peled-Zehavi; Joaquín M Pellegrini; Joffrey Pelletier; Miguel A Peñalva; Di Peng; Ying Peng; Fabio Penna; Maria Pennuto; Francesca Pentimalli; Cláudia Mf Pereira; Gustavo J S Pereira; Lilian C Pereira; Luis Pereira de Almeida; Nirma D Perera; Ángel Pérez-Lara; Ana B Perez-Oliva; María Esther Pérez-Pérez; Palsamy Periyasamy; Andras Perl; Cristiana Perrotta; Ida Perrotta; Richard G Pestell; Morten Petersen; Irina Petrache; Goran Petrovski; Thorsten Pfirrmann; Astrid S Pfister; Jennifer A Philips; Huifeng Pi; Anna Picca; Alicia M Pickrell; Sandy Picot; Giovanna M Pierantoni; Marina Pierdominici; Philippe Pierre; Valérie Pierrefite-Carle; Karolina Pierzynowska; Federico Pietrocola; Miroslawa Pietruczuk; Claudio Pignata; Felipe X Pimentel-Muiños; Mario Pinar; Roberta O Pinheiro; Ronit Pinkas-Kramarski; Paolo Pinton; Karolina Pircs; Sujan Piya; Paola Pizzo; Theo S Plantinga; Harald W Platta; Ainhoa Plaza-Zabala; Markus Plomann; Egor Y Plotnikov; Helene Plun-Favreau; Ryszard Pluta; Roger Pocock; Stefanie Pöggeler; Christian Pohl; Marc Poirot; Angelo Poletti; Marisa Ponpuak; Hana Popelka; Blagovesta Popova; Helena Porta; Soledad Porte Alcon; Eliana Portilla-Fernandez; Martin Post; Malia B Potts; Joanna Poulton; Ted Powers; Veena Prahlad; Tomasz K Prajsnar; Domenico Praticò; Rosaria Prencipe; Muriel Priault; Tassula Proikas-Cezanne; Vasilis J Promponas; Christopher G Proud; Rosa Puertollano; Luigi Puglielli; Thomas Pulinilkunnil; Deepika Puri; Rajat Puri; Julien Puyal; Xiaopeng Qi; Yongmei Qi; Wenbin Qian; Lei Qiang; Yu Qiu; Joe Quadrilatero; Jorge Quarleri; Nina Raben; Hannah Rabinowich; Debora Ragona; Michael J Ragusa; Nader Rahimi; Marveh Rahmati; Valeria Raia; Nuno Raimundo; Namakkal-Soorappan Rajasekaran; Sriganesh Ramachandra Rao; Abdelhaq Rami; Ignacio Ramírez-Pardo; David B Ramsden; Felix Randow; Pundi N Rangarajan; Danilo Ranieri; Hai Rao; Lang Rao; Rekha Rao; Sumit Rathore; J Arjuna Ratnayaka; Edward A Ratovitski; Palaniyandi Ravanan; Gloria Ravegnini; Swapan K Ray; Babak Razani; Vito Rebecca; Fulvio Reggiori; Anne Régnier-Vigouroux; Andreas S Reichert; David Reigada; Jan H Reiling; Theo Rein; Siegfried Reipert; Rokeya Sultana Rekha; Hongmei Ren; Jun Ren; Weichao Ren; Tristan Renault; Giorgia Renga; Karen Reue; Kim Rewitz; Bruna Ribeiro de Andrade Ramos; S Amer Riazuddin; Teresa M Ribeiro-Rodrigues; Jean-Ehrland Ricci; Romeo Ricci; Victoria Riccio; Des R Richardson; Yasuko Rikihisa; Makarand V Risbud; Ruth M Risueño; Konstantinos Ritis; Salvatore Rizza; Rosario Rizzuto; Helen C Roberts; Luke D Roberts; Katherine J Robinson; Maria Carmela Roccheri; Stephane Rocchi; George G Rodney; Tiago Rodrigues; Vagner Ramon Rodrigues Silva; Amaia Rodriguez; Ruth Rodriguez-Barrueco; Nieves Rodriguez-Henche; Humberto Rodriguez-Rocha; Jeroen Roelofs; Robert S Rogers; Vladimir V Rogov; Ana I Rojo; Krzysztof Rolka; Vanina Romanello; Luigina Romani; Alessandra Romano; Patricia S Romano; David Romeo-Guitart; Luis C Romero; Montserrat Romero; Joseph C Roney; Christopher Rongo; Sante Roperto; Mathias T Rosenfeldt; Philip Rosenstiel; Anne G Rosenwald; Kevin A Roth; Lynn Roth; Steven Roth; Kasper M A Rouschop; Benoit D Roussel; Sophie Roux; Patrizia Rovere-Querini; Ajit Roy; Aurore Rozieres; Diego Ruano; David C Rubinsztein; Maria P Rubtsova; Klaus Ruckdeschel; Christoph Ruckenstuhl; Emil Rudolf; Rüdiger Rudolf; Alessandra Ruggieri; Avnika Ashok Ruparelia; Paola Rusmini; Ryan R Russell; Gian Luigi Russo; Maria Russo; Rossella Russo; Oxana O Ryabaya; Kevin M Ryan; Kwon-Yul Ryu; Maria Sabater-Arcis; Ulka Sachdev; Michael Sacher; Carsten Sachse; Abhishek Sadhu; Junichi Sadoshima; Nathaniel Safren; Paul Saftig; Antonia P Sagona; Gaurav Sahay; Amirhossein Sahebkar; Mustafa Sahin; Ozgur Sahin; Sumit Sahni; Nayuta Saito; Shigeru Saito; Tsunenori Saito; Ryohei Sakai; Yasuyoshi Sakai; Jun-Ichi Sakamaki; Kalle Saksela; Gloria Salazar; Anna Salazar-Degracia; Ghasem H Salekdeh; Ashok K Saluja; Belém Sampaio-Marques; Maria Cecilia Sanchez; Jose A Sanchez-Alcazar; Victoria Sanchez-Vera; Vanessa Sancho-Shimizu; J Thomas Sanderson; Marco Sandri; Stefano Santaguida; Laura Santambrogio; Magda M Santana; Giorgio Santoni; Alberto Sanz; Pascual Sanz; Shweta Saran; Marco Sardiello; Timothy J Sargeant; Apurva Sarin; Chinmoy Sarkar; Sovan Sarkar; Maria-Rosa Sarrias; Surajit Sarkar; Dipanka Tanu Sarmah; Jaakko Sarparanta; Aishwarya Sathyanarayan; Ranganayaki Sathyanarayanan; K Matthew Scaglione; Francesca Scatozza; Liliana Schaefer; Zachary T Schafer; Ulrich E Schaible; Anthony H V Schapira; Michael Scharl; Hermann M Schatzl; Catherine H Schein; Wiep Scheper; David Scheuring; Maria Vittoria Schiaffino; Monica Schiappacassi; Rainer Schindl; Uwe Schlattner; Oliver Schmidt; Roland Schmitt; Stephen D Schmidt; Ingo Schmitz; Eran Schmukler; Anja Schneider; Bianca E Schneider; Romana Schober; Alejandra C Schoijet; Micah B Schott; Michael Schramm; Bernd Schröder; Kai Schuh; Christoph Schüller; Ryan J Schulze; Lea Schürmanns; Jens C Schwamborn; Melanie Schwarten; Filippo Scialo; Sebastiano Sciarretta; Melanie J Scott; Kathleen W Scotto; A Ivana Scovassi; Andrea Scrima; Aurora Scrivo; David Sebastian; Salwa Sebti; Simon Sedej; Laura Segatori; Nava Segev; Per O Seglen; Iban Seiliez; Ekihiro Seki; Scott B Selleck; Frank W Sellke; Joshua T Selsby; Michael Sendtner; Serif Senturk; Elena Seranova; Consolato Sergi; Ruth Serra-Moreno; Hiromi Sesaki; Carmine Settembre; Subba Rao Gangi Setty; Gianluca Sgarbi; Ou Sha; John J Shacka; Javeed A Shah; Dantong Shang; Changshun Shao; Feng Shao; Soroush Sharbati; Lisa M Sharkey; Dipali Sharma; Gaurav Sharma; Kulbhushan Sharma; Pawan Sharma; Surendra Sharma; Han-Ming Shen; Hongtao Shen; Jiangang Shen; Ming Shen; Weili Shen; Zheni Shen; Rui Sheng; Zhi Sheng; Zu-Hang Sheng; Jianjian Shi; Xiaobing Shi; Ying-Hong Shi; Kahori Shiba-Fukushima; Jeng-Jer Shieh; Yohta Shimada; Shigeomi Shimizu; Makoto Shimozawa; Takahiro Shintani; Christopher J Shoemaker; Shahla Shojaei; Ikuo Shoji; Bhupendra V Shravage; Viji Shridhar; Chih-Wen Shu; Hong-Bing Shu; Ke Shui; Arvind K Shukla; Timothy E Shutt; Valentina Sica; Aleem Siddiqui; Amanda Sierra; Virginia Sierra-Torre; Santiago Signorelli; Payel Sil; Bruno J de Andrade Silva; Johnatas D Silva; Eduardo Silva-Pavez; Sandrine Silvente-Poirot; Rachel E Simmonds; Anna Katharina Simon; Hans-Uwe Simon; Matias Simons; Anurag Singh; Lalit P Singh; Rajat Singh; Shivendra V Singh; Shrawan K Singh; Sudha B Singh; Sunaina Singh; Surinder Pal Singh; Debasish Sinha; Rohit Anthony Sinha; Sangita Sinha; Agnieszka Sirko; Kapil Sirohi; Efthimios L Sivridis; Panagiotis Skendros; Aleksandra Skirycz; Iva Slaninová; Soraya S Smaili; Andrei Smertenko; Matthew D Smith; Stefaan J Soenen; Eun Jung Sohn; Sophia P M Sok; Giancarlo Solaini; Thierry Soldati; Scott A Soleimanpour; Rosa M Soler; Alexei Solovchenko; Jason A Somarelli; Avinash Sonawane; Fuyong Song; Hyun Kyu Song; Ju-Xian Song; Kunhua Song; Zhiyin Song; Leandro R Soria; Maurizio Sorice; Alexander A Soukas; Sandra-Fausia Soukup; Diana Sousa; Nadia Sousa; Paul A Spagnuolo; Stephen A Spector; M M Srinivas Bharath; Daret St Clair; Venturina Stagni; Leopoldo Staiano; Clint A Stalnecker; Metodi V Stankov; Peter B Stathopulos; Katja Stefan; Sven Marcel Stefan; Leonidas Stefanis; Joan S Steffan; Alexander Steinkasserer; Harald Stenmark; Jared Sterneckert; Craig Stevens; Veronika Stoka; Stephan Storch; Björn Stork; Flavie Strappazzon; Anne Marie Strohecker; Dwayne G Stupack; Huanxing Su; Ling-Yan Su; Longxiang Su; Ana M Suarez-Fontes; Carlos S Subauste; Selvakumar Subbian; Paula V Subirada; Ganapasam Sudhandiran; Carolyn M Sue; Xinbing Sui; Corey Summers; Guangchao Sun; Jun Sun; Kang Sun; Meng-Xiang Sun; Qiming Sun; Yi Sun; Zhongjie Sun; Karen K S Sunahara; Eva Sundberg; Katalin Susztak; Peter Sutovsky; Hidekazu Suzuki; Gary Sweeney; J David Symons; Stephen Cho Wing Sze; Nathaniel J Szewczyk; Anna Tabęcka-Łonczynska; Claudio Tabolacci; Frank Tacke; Heinrich Taegtmeyer; Marco Tafani; Mitsuo Tagaya; Haoran Tai; Stephen W G Tait; Yoshinori Takahashi; Szabolcs Takats; Priti Talwar; Chit Tam; Shing Yau Tam; Davide Tampellini; Atsushi Tamura; Chong Teik Tan; Eng-King Tan; Ya-Qin Tan; Masaki Tanaka; Motomasa Tanaka; Daolin Tang; Jingfeng Tang; Tie-Shan Tang; Isei Tanida; Zhipeng Tao; Mohammed Taouis; Lars Tatenhorst; Nektarios Tavernarakis; Allen Taylor; Gregory A Taylor; Joan M Taylor; Elena Tchetina; Andrew R Tee; Irmgard Tegeder; David Teis; Natercia Teixeira; Fatima Teixeira-Clerc; Kumsal A Tekirdag; Tewin Tencomnao; Sandra Tenreiro; Alexei V Tepikin; Pilar S Testillano; Gianluca Tettamanti; Pierre-Louis Tharaux; Kathrin Thedieck; Arvind A Thekkinghat; Stefano Thellung; Josephine W Thinwa; V P Thirumalaikumar; Sufi Mary Thomas; Paul G Thomes; Andrew Thorburn; Lipi Thukral; Thomas Thum; Michael Thumm; Ling Tian; Ales Tichy; Andreas Till; Vincent Timmerman; Vladimir I Titorenko; Sokol V Todi; Krassimira Todorova; Janne M Toivonen; Luana Tomaipitinca; Dhanendra Tomar; Cristina Tomas-Zapico; Sergej Tomić; Benjamin Chun-Kit Tong; Chao Tong; Xin Tong; Sharon A Tooze; Maria L Torgersen; Satoru Torii; Liliana Torres-López; Alicia Torriglia; Christina G Towers; Roberto Towns; Shinya Toyokuni; Vladimir Trajkovic; Donatella Tramontano; Quynh-Giao Tran; Leonardo H Travassos; Charles B Trelford; Shirley Tremel; Ioannis P Trougakos; Betty P Tsao; Mario P Tschan; Hung-Fat Tse; Tak Fu Tse; Hitoshi Tsugawa; Andrey S Tsvetkov; David A Tumbarello; Yasin Tumtas; María J Tuñón; Sandra Turcotte; Boris Turk; Vito Turk; Bradley J Turner; Richard I Tuxworth; Jessica K Tyler; Elena V Tyutereva; Yasuo Uchiyama; Aslihan Ugun-Klusek; Holm H Uhlig; Marzena Ułamek-Kozioł; Ilya V Ulasov; Midori Umekawa; Christian Ungermann; Rei Unno; Sylvie Urbe; Elisabet Uribe-Carretero; Suayib Üstün; Vladimir N Uversky; Thomas Vaccari; Maria I Vaccaro; Björn F Vahsen; Helin Vakifahmetoglu-Norberg; Rut Valdor; Maria J Valente; Ayelén Valko; Richard B Vallee; Angela M Valverde; Greet Van den Berghe; Stijn van der Veen; Luc Van Kaer; Jorg van Loosdregt; Sjoerd J L van Wijk; Wim Vandenberghe; Ilse Vanhorebeek; Marcos A Vannier-Santos; Nicola Vannini; M Cristina Vanrell; Chiara Vantaggiato; Gabriele Varano; Isabel Varela-Nieto; Máté Varga; M Helena Vasconcelos; Somya Vats; Demetrios G Vavvas; Ignacio Vega-Naredo; Silvia Vega-Rubin-de-Celis; Guillermo Velasco; Ariadna P Velázquez; Tibor Vellai; Edo Vellenga; Francesca Velotti; Mireille Verdier; Panayotis Verginis; Isabelle Vergne; Paul Verkade; Manish Verma; Patrik Verstreken; Tim Vervliet; Jörg Vervoorts; Alexandre T Vessoni; Victor M Victor; Michel Vidal; Chiara Vidoni; Otilia V Vieira; Richard D Vierstra; Sonia Viganó; Helena Vihinen; Vinoy Vijayan; Miquel Vila; Marçal Vilar; José M Villalba; Antonio Villalobo; Beatriz Villarejo-Zori; Francesc Villarroya; Joan Villarroya; Olivier Vincent; Cecile Vindis; Christophe Viret; Maria Teresa Viscomi; Dora Visnjic; Ilio Vitale; David J Vocadlo; Olga V Voitsekhovskaja; Cinzia Volonté; Mattia Volta; Marta Vomero; Clarissa Von Haefen; Marc A Vooijs; Wolfgang Voos; Ljubica Vucicevic; Richard Wade-Martins; Satoshi Waguri; Kenrick A Waite; Shuji Wakatsuki; David W Walker; Mark J Walker; Simon A Walker; Jochen Walter; Francisco G Wandosell; Bo Wang; Chao-Yung Wang; Chen Wang; Chenran Wang; Chenwei Wang; Cun-Yu Wang; Dong Wang; Fangyang Wang; Feng Wang; Fengming Wang; Guansong Wang; Han Wang; Hao Wang; Hexiang Wang; Hong-Gang Wang; Jianrong Wang; Jigang Wang; Jiou Wang; Jundong Wang; Kui Wang; Lianrong Wang; Liming Wang; Maggie Haitian Wang; Meiqing Wang; Nanbu Wang; Pengwei Wang; Peipei Wang; Ping Wang; Ping Wang; Qing Jun Wang; Qing Wang; Qing Kenneth Wang; Qiong A Wang; Wen-Tao Wang; Wuyang Wang; Xinnan Wang; Xuejun Wang; Yan Wang; Yanchang Wang; Yanzhuang Wang; Yen-Yun Wang; Yihua Wang; Yipeng Wang; Yu Wang; Yuqi Wang; Zhe Wang; Zhenyu Wang; Zhouguang Wang; Gary Warnes; Verena Warnsmann; Hirotaka Watada; Eizo Watanabe; Maxinne Watchon; Anna Wawrzyńska; Timothy E Weaver; Grzegorz Wegrzyn; Ann M Wehman; Huafeng Wei; Lei Wei; Taotao Wei; Yongjie Wei; Oliver H Weiergräber; Conrad C Weihl; Günther Weindl; Ralf Weiskirchen; Alan Wells; Runxia H Wen; Xin Wen; Antonia Werner; Beatrice Weykopf; Sally P Wheatley; J Lindsay Whitton; Alexander J Whitworth; Katarzyna Wiktorska; Manon E Wildenberg; Tom Wileman; Simon Wilkinson; Dieter Willbold; Brett Williams; Robin S B Williams; Roger L Williams; Peter R Williamson; Richard A Wilson; Beate Winner; Nathaniel J Winsor; Steven S Witkin; Harald Wodrich; Ute Woehlbier; Thomas Wollert; Esther Wong; Jack Ho Wong; Richard W Wong; Vincent Kam Wai Wong; W Wei-Lynn Wong; An-Guo Wu; Chengbiao Wu; Jian Wu; Junfang Wu; Kenneth K Wu; Min Wu; Shan-Ying Wu; Shengzhou Wu; Shu-Yan Wu; Shufang Wu; William K K Wu; Xiaohong Wu; Xiaoqing Wu; Yao-Wen Wu; Yihua Wu; Ramnik J Xavier; Hongguang Xia; Lixin Xia; Zhengyuan Xia; Ge Xiang; Jin Xiang; Mingliang Xiang; Wei Xiang; Bin Xiao; Guozhi Xiao; Hengyi Xiao; Hong-Tao Xiao; Jian Xiao; Lan Xiao; Shi Xiao; Yin Xiao; Baoming Xie; Chuan-Ming Xie; Min Xie; Yuxiang Xie; Zhiping Xie; Zhonglin Xie; Maria Xilouri; Congfeng Xu; En Xu; Haoxing Xu; Jing Xu; JinRong Xu; Liang Xu; Wen Wen Xu; Xiulong Xu; Yu Xue; Sokhna M S Yakhine-Diop; Masamitsu Yamaguchi; Osamu Yamaguchi; Ai Yamamoto; Shunhei Yamashina; Shengmin Yan; Shian-Jang Yan; Zhen Yan; Yasuo Yanagi; Chuanbin Yang; Dun-Sheng Yang; Huan Yang; Huang-Tian Yang; Hui Yang; Jin-Ming Yang; Jing Yang; Jingyu Yang; Ling Yang; Liu Yang; Ming Yang; Pei-Ming Yang; Qian Yang; Seungwon Yang; Shu Yang; Shun-Fa Yang; Wannian Yang; Wei Yuan Yang; Xiaoyong Yang; Xuesong Yang; Yi Yang; Ying Yang; Honghong Yao; Shenggen Yao; Xiaoqiang Yao; Yong-Gang Yao; Yong-Ming Yao; Takahiro Yasui; Meysam Yazdankhah; Paul M Yen; Cong Yi; Xiao-Ming Yin; Yanhai Yin; Zhangyuan Yin; Ziyi Yin; Meidan Ying; Zheng Ying; Calvin K Yip; Stephanie Pei Tung Yiu; Young H Yoo; Kiyotsugu Yoshida; Saori R Yoshii; Tamotsu Yoshimori; Bahman Yousefi; Boxuan Yu; Haiyang Yu; Jun Yu; Jun Yu; Li Yu; Ming-Lung Yu; Seong-Woon Yu; Victor C Yu; W Haung Yu; Zhengping Yu; Zhou Yu; Junying Yuan; Ling-Qing Yuan; Shilin Yuan; Shyng-Shiou F Yuan; Yanggang Yuan; Zengqiang Yuan; Jianbo Yue; Zhenyu Yue; Jeanho Yun; Raymond L Yung; David N Zacks; Gabriele Zaffagnini; Vanessa O Zambelli; Isabella Zanella; Qun S Zang; Sara Zanivan; Silvia Zappavigna; Pilar Zaragoza; Konstantinos S Zarbalis; Amir Zarebkohan; Amira Zarrouk; Scott O Zeitlin; Jialiu Zeng; Ju-Deng Zeng; Eva Žerovnik; Lixuan Zhan; Bin Zhang; Donna D Zhang; Hanlin Zhang; Hong Zhang; Hong Zhang; Honghe Zhang; Huafeng Zhang; Huaye Zhang; Hui Zhang; Hui-Ling Zhang; Jianbin Zhang; Jianhua Zhang; Jing-Pu Zhang; Kalin Y B Zhang; Leshuai W Zhang; Lin Zhang; Lisheng Zhang; Lu Zhang; Luoying Zhang; Menghuan Zhang; Peng Zhang; Sheng Zhang; Wei Zhang; Xiangnan Zhang; Xiao-Wei Zhang; Xiaolei Zhang; Xiaoyan Zhang; Xin Zhang; Xinxin Zhang; Xu Dong Zhang; Yang Zhang; Yanjin Zhang; Yi Zhang; Ying-Dong Zhang; Yingmei Zhang; Yuan-Yuan Zhang; Yuchen Zhang; Zhe Zhang; Zhengguang Zhang; Zhibing Zhang; Zhihai Zhang; Zhiyong Zhang; Zili Zhang; Haobin Zhao; Lei Zhao; Shuang Zhao; Tongbiao Zhao; Xiao-Fan Zhao; Ying Zhao; Yongchao Zhao; Yongliang Zhao; Yuting Zhao; Guoping Zheng; Kai Zheng; Ling Zheng; Shizhong Zheng; Xi-Long Zheng; Yi Zheng; Zu-Guo Zheng; Boris Zhivotovsky; Qing Zhong; Ao Zhou; Ben Zhou; Cefan Zhou; Gang Zhou; Hao Zhou; Hong Zhou; Hongbo Zhou; Jie Zhou; Jing Zhou; Jing Zhou; Jiyong Zhou; Kailiang Zhou; Rongjia Zhou; Xu-Jie Zhou; Yanshuang Zhou; Yinghong Zhou; Yubin Zhou; Zheng-Yu Zhou; Zhou Zhou; Binglin Zhu; Changlian Zhu; Guo-Qing Zhu; Haining Zhu; Hongxin Zhu; Hua Zhu; Wei-Guo Zhu; Yanping Zhu; Yushan Zhu; Haixia Zhuang; Xiaohong Zhuang; Katarzyna Zientara-Rytter; Christine M Zimmermann; Elena Ziviani; Teresa Zoladek; Wei-Xing Zong; Dmitry B Zorov; Antonio Zorzano; Weiping Zou; Zhen Zou; Zhengzhi Zou; Steven Zuryn; Werner Zwerschke; Beate Brand-Saberi; X Charlie Dong; Chandra Shekar Kenchappa; Zuguo Li; Yong Lin; Shigeru Oshima; Yueguang Rong; Judith C Sluimer; Christina L Stallings; Chun-Kit Tong Journal: Autophagy Date: 2021-02-08 Impact factor: 13.391
Authors: Débora Lanznaster; Charlotte Veyrat-Durebex; Patrick Vourc'h; Christian R Andres; Hélène Blasco; Philippe Corcia Journal: Genes (Basel) Date: 2020-05-11 Impact factor: 4.096